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ABSTRACT  
   
 The concept of vaccination dates back further than Edward Jenner's first 
vaccine using cowpox pustules to confer immunity against smallpox in 1796. 
Nevertheless, it was Jenner's success that gave vaccines their name and made 
vaccinia virus (VACV) of particular interest. More than 200 years later there is 
still the need to understand vaccination from vaccine design to prediction of 
vaccine efficacy using mathematical models. Post-exposure vaccination with 
VACV has been suggested to be effective if administered within four days of 
smallpox exposure although this has not been definitively studied in humans.  
The first and second chapters analyze post-exposure prophylaxis of VACV in an 
animal model using v50ΔB13RMγ, a recombinant VACV expressing murine 
interferon gamma (IFN-γ) also known as type II IFN. While untreated animals 
infected with wild type VACV die by 10 days post-infection (dpi), animals treated 
with v50ΔB13RMγ 1 dpi had decreased morbidity and 100% survival. Despite 
these differences, the viral load was similar in both groups suggesting that 
v50ΔB13RMγ acts as an immunoregulator rather than as an antiviral. One of the 
main characteristics of VACV is its resistance to type I IFN, an effect primarily 
mediated by the E3L protein, which has a Z-DNA binding domain and a double-
stranded RNA (dsRNA) binding domain. In the third chapter a VACV that 
independently expresses both domains of E3L was engineered and compared to 
wild type in cells in culture. The dual expression virus was unable to replicate in 
the JC murine cell line where both domains are needed together for replication. 
Moreover, phosphorylation of the dsRNA dependent protein kinase (PKR) was 
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observed at late times post-infection which indicates that both domains need to be 
linked together in order to block the IFN response. Because smallpox has already 
been eradicated, the utility of mathematical modeling as a tool for predicting 
disease spread and vaccine efficacy was explored in the last chapter using dengue 
as a disease model. Current modeling approaches were reviewed and the 2000-
2001 dengue outbreak in a Peruvian region was analyzed. This last section 
highlights the importance of interdisciplinary collaboration and how it benefits 
research on infectious diseases. 
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OVERALL INTRODUCTION 
 The importance of vaccines and the concept of vaccination dates back to 
1796 and Edward Jenner's most important health intervention in history when he 
used cowpox pustules to confer immunity against smallpox (108, 197). Jenner's 
contributions led to eradication of smallpox and made him founder of the new 
science of vaccinology (46). Of special interest is vaccinia virus (VACV), which 
is believed to have evolved from variola virus (VARV), cowpox virus or a hybrid 
of both (218). VACV have been routinely used as a vaccine for smallpox as it 
provides cross-protection to VARV, the causative agent for smallpox (108). Now, 
more than 200 years later and following the eradication of smallpox in the late 
1970s (4, 237), there is still the need to understand vaccination from vaccine 
design to prediction of vaccine efficacy using mathematical models.  
Following smallpox eradication, routine smallpox vaccination was 
discontinued in the U.S. in 1972 (4). This left the majority of the world population 
susceptible to severe diseases from certain orthopoxvirus infections. After 
September 11, 2001, there was heightened concern for the use of VARV or 
monkeypox virus (MPXV) as a bioterrorism agent and the low, but real, risk of an 
accidental VARV release (134, 169, 227). Moreover, inoculation in humans with 
VACV can lead from mild to life-threatening reactions and these complications 
vary according to each VACV strain (58, 127, 206). All these reasons make the 
need of a post-exposure prophylaxis vaccine for smallpox one of the ultimate 
worldwide goals. Post-exposure vaccination using VACV has been suggested to 
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be effective against smallpox if administered within four days of initial exposure 
(157). While there is anecdotal evidence for efficacy of post-exposure 
vaccination, this has not been definitively studied in humans.  
There are diverse antiviral agents that have been used for post-exposure 
treatment of smallpox. Of these it is worth to mention (S)-1-(3-hydroxy-2-
phosphonylmethoxypropyl)-cytosine also known as HPMPC, Vistide, and 
cidofovir (45, 222), although its use is limited due to nephrotoxicity and the lack 
of oral availability (222). Another antiviral agent is vaccine immune globulin 
(VIG), which has been suggested to be used by patients for whom smallpox 
vaccine is contraindicated (240). The most promising anti-poxviral drug and post-
exposure agent is ST-246 (167, 185, 186, 219, 246), which have been used to 
protect ground squirrels that have been infected with MPXV (209) and in 
combination therapy with other compounds to treat humans exposed to VACV 
(29-31, 231). 
Post-exposure has been recently studied using modified VACV Ankara 
(MVA) and the VACV-Lister strain for post-exposure treatment in the murine 
model (173, 221). While immunization with MVA and the Lister strain proved to 
be effective against an ECTV infection when post-exposure was performed up to 
3 days post-infection (dpi) (173), post-exposure vaccination with MVA was 
effective at 1 dpi after challenge with the Western Reserve (WR) strain of VACV 
(221). Moreover, post-exposure treatment with the Lister strain failed to provide 
any protection (221). 
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 The approach for post-exposure prophylaxis that was used in the first 
chapter of this dissertation relies in the fact that VACV allows the insertion of 
foreign DNA using double-homologous recombination and that certain cytokines 
have shown to decrease virulence during VACV infection (70, 163, 191, 212). In 
this context a recombinant VACV expressing murine IFN-γ (v50ΔB13RMγ), 
which has previously been described (136), was found to be the best candidate in 
an animal model for post-exposure treatment following a challenge with wild type 
VACV (WR strain). Post-exposure protection with v50ΔB13RMγ was dose and 
time dependent with 100% survival in animals treated 1 dpi. The mechanism of 
action for post-exposure treatment using v50ΔB13RMγ is explored in Chapter 2. 
The effects of this virus at the site of infection can be observed by 2 dpi with the 
recruitment of specialized myeloid derived suppressor cells whose role in post-
exposure protection is yet to be determined. Moreover, activation of the inducible 
nitric oxide synthase by IFN-γ could be playing a role in the survival of the 
animals. 
 While the first two chapters describe the use of a recombinant VACV that 
expresses IFN-γ for post-exposure treatment, one of the innate characteristics of 
VACV is that it is IFN-resistant. This characteristic is primarily due to the E3L 
gene (106) which has also been associated to neurovirulence in mice (19, 122). 
E3L encodes a 25-kDa protein that has two essential domains, an N-terminal 
domain with sequence similarity to the vertebrate Zα family of Z-DNA binding 
domains (110, 121, 122, 129), and a C-terminal domain that has a typical double-
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stranded RNA (dsRNA) binding domain (34, 43, 133). Furthermore, the E3L gene 
is a common feature of orthopox viruses. In fact, when comparing VACV and 
VARV, the N-terminal and C-terminal E3L domains are both nearly identical 
(187). 
 Deletion of E3L leads to a virus that is completely non-pathogenic (19, 
35). Unfortunately, expression of foreign genes from this virus is also greatly 
reduced (109). The E3L gene is involved in inhibiting the host antiviral response.  
The C-terminal domain of E3L has been previously characterized and its function 
is to bind and mask dsRNA synthesized during VACV infection (34, 102, 103).  
In the absence of E3L, the dsRNA dependent protein kinase (PKR) binds to 
dsRNA, dimerizes and becomes autophosphorylated. This activation of PKR 
leads to phosphorylation of the eukaryotic initiation factor 2 alpha subunit (eIF2α) 
which becomes inactivated and halts translation of viral and host proteins (36, 
119). Moreover, analysis of several VACV with mutations in the dsRNA binding 
domain demonstrated that E3L can bind to PKR suggesting that this interaction 
can enhance the inhibition of PKR activation by sequestering the dsRNA activator 
(177). 
 Although the C-terminus has been associated with IFN resistance and 
PKR inhibition, recent data showed that the N-terminus is also necessary for both 
mechanisms providing a new insight into the function of the Z-DNA binding 
domain in vivo (235). This N-terminus domain has also been associated with 
neurovirulence and neuroinvasion following VACV infection in C57/BL6 mice 
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(18, 122). Furthermore, it is necessary to inhibit PKR activation at late times post-
infection as well as eIF2α phosphorylation in HeLa cells and in nasal turbinates of 
C57/BL6 mice (132).   
  The third chapter explores the role of the Z-DNA binding domain and its 
independent expression from the dsRNA binding domain. A dual expression virus 
was engineered and compared to wild type VACV in cells in culture and for its 
ability to inactivate the IFN response. The dual expression virus was unable to 
replicate in the murine JC cell line, a previously described cell line where E3L 
mutants lacking either the Z-DNA binding domain or the dsRNA binding domain 
are unable to replicate (228). Moreover, PKR phosphorylation was observed at 
late times post-infection indicating that both domains of E3L need to be linked 
together in order to block the IFN response.  
 Because smallpox has already been eradicated, the utility of mathematical 
modeling as a tool for predicting vaccine efficacy was explored in the fourth 
chapter using dengue as a disease model. Dengue virus, is a single-stranded, 
positive-sense RNA virus that belongs to family Flaviviridae (49). Dengue has 
four antigenically different serotypes also known as DENV-1, DENV-2, DENV-3 
and DENV-4. The pathogenicity of the disease ranges from asymptomatic or mild 
dengue fever (DF) to the more severe dengue hemorrhagic fever (DHF) and 
dengue shock syndrome (DSS), which affect mostly children under 15 (49, 93). 
 The World Health Organization has declared that two fifths of the world 
population are at risk of being infected with dengue and although dengue has been 
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commonly presented as a tropical disease, it has spread to U.S. (32, 236). It is 
clear that dengue has expanded to a vast amount of territories, in part due to the 
adaptation of one of mosquito vectors, Aedes albopictus, to colder climates (101, 
156) and the evidence of vertical transmission from the infected female to her 
eggs in both Aedes aegypti, the primary vector, and Aedes albopictus (9, 17, 33, 
89, 126, 203). 
  One of the main issues with dengue is that there is not yet a commercial 
available vaccine although many efforts are being made by diverse research 
groups in academic and industrial settings (53). These vaccine candidates include 
live vaccines, attenuated vaccines, vaccines created using recombinant DNA 
technology, as well as subunit vaccines like the ones developed by Merck/Hawaii 
Biotech (90). Of these vaccines, the tetravalent dengue vaccine from Sanofi 
Pasteur was the first one to go into Phase III of clinical trials and results are 
expected by the end of 2012 (91).  
 Dengue is considered one of the most important emerging and re-
emerging infectious diseases worldwide (93, 98, 178, 236). It will require a 
multidisciplinary effort to fully understand the complex dynamic of dengue and 
the efficacy of the introduction of a vaccine candidate. This is in part due to the 
complexity of the  immunology, epidemiology, pathology and the interactions 
between the vector and the host. In 2010 the World Health Organization 
organized a workshop designed to bring together mathematical modelers, 
clinicians, vaccinologists, virologists, immunologists, entomologists and 
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epidemiologists to explore what is currently being done and what needs to be 
done with respect to dengue vaccine modeling (238).  
 The fourth chapter provides an overview of current dengue transmission 
models and their diverse challenges, as they cannot predict for example an early 
rainy season and how this will affect the outcome of the model. Understanding the 
current dengue models will lead to a better evaluation of the efficacy of future 
vaccination strategies. Thus, it is of great importance that scientists across 
disciplines come together and evaluate the use of mathematical models as tools to 
understand the risks and potential successes or pitfalls of vaccination strategies 
worldwide.  
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CHAPTER 1 
POST-EXPOSURE ADMINISTRATION OF A RECOMBINANT 
VACCINIA VIRUS EXPRESSING INTERFERON GAMMA PROTECTS 
MICE FROM LETHAL INTRANASAL INFECTIONS WITH VACCINIA 
VIRUS   
 
 ABSTRACT 
 Post-exposure vaccination with vaccinia virus (VACV) has been 
suggested to be effective in minimizing death if administered within four days  
of smallpox exposure. While there is anecdotal evidence for efficacy of post-
exposure vaccination this has not been definitively studied in humans. The 
experiments analyze post-exposure prophylaxis of VACV in an animal model 
using VACV E3L mutants as well as recombinant VACV expressing murine 
interferon-γ (IFN-γ) or murine interleukin-18 (IL-18). A recombinant VACV 
expressing murine IFN-γ was most effective at post-exposure protection of mice 
infected with VACV. While all untreated animals infected with VACV exhibited 
severe weight loss and morbidity leading to 100% mortality by 8 to 10 days post-
infection, animals treated one day post-infection had milder symptoms, decreased 
weight loss and morbidity, and 100% survival. Treatment on days 2 or 3 post-
infection resulted in 40% and 20% survival, respectively. Despite the differences 
in survival rates when animals were treated at 1 day post-infection, the viral load 
was similar in both treated and untreated mice.  These results suggest that 
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protection provided by IFN-γ expressed by VACV is mediated by its 
immunoregulatory activities rather than its antiviral effects.  
 
INTRODUCTION 
 Vaccinia virus (VACV) is a member of the genus Orthopoxvirus of the 
family Poxviridae. Other members of this family include variola virus (VARV), 
the causative agent of smallpox; monkeypox virus (MPXV), ectromelia virus 
(ECTV), camelpox virus (CMLV) and cowpox virus (CPXV) (66, 159). After an 
intensive vaccination strategy using VACV, which was initiated in 1967, 
smallpox was declared eradicated from the world in 1980 and routine smallpox 
vaccination was discontinued in the U.S. in 1972 (4, 237). This left the majority 
of the world population susceptible to severe disease from certain orthopoxvirus 
infections. After September 11, 2001, there was heightened concern for the use of 
VARV or MPXV as a bioterrorism agent and the low, but real, risk of an 
accidental VARV release (134, 169, 227). For these reasons it was important to 
develop a post-exposure prophylaxis strategy.  
There are diverse antiviral agents that have been considered as alternative 
strategies for post-exposure treatment of smallpox. One of the antiviral drugs that 
has been shown to be effective against different poxviruses is (S)-1-(3-hydroxy-2-
phosphonylmethoxypropyl)-cytosine also known as HPMPC, Vistide, and more 
commonly as cidofovir (45, 222). While cidofovir has been shown to protect 
monkeypox-infected macaques when administered 24 hours post-infection (hpi), 
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its potential is limited by nephrotoxicity and the lack of oral availability (222). 
Likewise, vaccine immune globulin (VIG), has also been suggested to be used as 
prophylaxis in patients for whom smallpox vaccine is contraindicated (240).  
Another antiviral, ST-246, has shown promise as an antipoxviral drug 
(167, 185, 186, 219, 246). ST-246 protects ground squirrels against monkeypox 
challenge when administered up to 3 days post-exposure (209). Treatment with 
VIGIV (VIG Intravenous) and cidofovir along with ST-246 (multiple doses) has 
proven to be successful in the treatment of a 28-month-old child with severe 
eczema vaccinatum (29, 231). Similarly, a combination therapy using VIGIV, ST-
246, Imiquimod and CMX001, a lipid conjugate of cidofovir, were used to treat 
progressive vaccinia in a military vaccinee (31). Moreover, VIGIV and ST-246 
have recently been used to treat human vaccinia infection in a 35 year-old woman 
after contact with raccoon rabies bait (30). Although it is difficult to assess the 
contribution of each agent because of the close timing of administration, these 
cases are an example of the utility of new treatments. 
 Post-exposure vaccination with VACV has also been suggested to be an 
effective treatment if administered within four days of smallpox exposure (157). 
While there is anecdotal evidence for efficacy of post-exposure vaccination this 
has not been definitively studied in humans.  
A recent model of post-exposure immunization with modified VACV 
Ankara (MVA) and the VACV-Lister strain proved to be effective in an ECTV 
infection model when post-exposure vaccination was performed at 1, 2 and 3 days 
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post-infection (dpi). Protection was shown to be dependant on the vaccine dose as 
well as the day of vaccination (173). A second model employs the Western 
Reserve (WR) strain of VACV as a challenge virus in mice. Therapeutic 
vaccination with MVA was minimally protective only at 1 dpi while the Elstree 
strain failed to provide any detectable protection (221). 
Because cytokines are highly regulated during VACV infection, they have 
been thoroughly studied in this context (70, 163, 191, 212). While IL-2, TNF-α 
and IFN-γ decrease virulence during a VACV infection, others such as IL-4 have 
been shown to increase virulence and pathogenicity (70, 163, 191, 212). Another 
cytokine, IL-18, which can induce endogenous synthesis of IFN-γ, has been 
shown to promote clearance of VACV infection when expressed together with IL-
12, indicating the synergistic action of both cytokines (78).  
The present work employed recombinant VACV for post-exposure 
prophylaxis in an animal model. Several recombinant VACVs as therapeutic 
vaccines were evaluated including 1) viruses containing mutations in the VACV 
E3L gene, an IFN resistance gene (19, 213) and 2) viruses expressing murine 
IFN-γ (muIFN-γ) (136) or murine IL-18 (muIL-18) from the VACV B13R locus. 
 This chapter outlines the use of different VACV E3L mutants and VACV 
recombinant viruses for post-exposure prophylaxis treatment. The results show 
that post-exposure prophylaxis with a recombinant VACV expressing IFN-γ is 
100% effective in protecting mice infected with 100 LD50s of wt VACV when 
administered 1 dpi.  
 12 
MATERIALS AND METHODS 
 Recombinant viruses. The WR strain of VACV was used as the parental 
virus for these studies. The E3L VACV mutants were generated by standard 
methods routinely employed in Dr. Bertram Jacobs' laboratory. Construction of 
VACV mutants expressing E3LΔ7C and E3LΔ26C has previously been described 
(119). VACVΔE3L::ATVeIF2α has a replacement of the E3L gene with the 
eukaryotic initiation factor 2 alpha (eIF2α) homologue from the Ambystoma 
tigrinum virus, genus Ranavirus, family Iridoviridae (131).   
The recombinant VACV expressing IFN-γ (v50ΔB13RMγ) virus was 
constructed as previously described (136). This virus expresses the vesicular 
stomatitis virus glycoprotein (VSV-G) at the TK locus and lacZ, gpt, and muIFN-
γ at the B13R site. The recombinant VACV expressing IL-18 
(v50ΔB13RMIL-18) is essentially the same as v50ΔB13RMγ, but expresses the 
muIL-18 gene instead of muIFN-γ. The muIL-18 gene was cloned from mouse 
spleen cDNA (Verardi et al., manuscript in preparation). Construction of the 
parental virus (v50ΔB13R) has already been described (137).   
Cell culture. Viruses were amplified in Baby Hamster Kidney 21 (BHK) 
cells and partially purified by pelleting through a 36% sucrose pad, as previously 
described (15, 54). BHK and Rabbit Kidney 13 (RK13) cells were cultured in 
Eagle's Minimal Essential Medium (MEM, Gibco, BRL) containing 5% fetal 
bovine serum (FBS, Hyclone), 50 µg/ml of gentamycin, and 0.1 mM nonessential  
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amino acid solution (Gibco, BRL) and vitamin supplements. Both BHK and RK-
13 cells were incubated at 37˚C with 5% CO2.   
 Mice. Four-week old female C57BL/6 mice were obtained from Charles 
River Laboratories. Mice were housed at the Arizona State University Department 
of Animal Care and Technologies according to the university IACUC regulations. 
Each cage contained a maximum of 5 mice and a separate cage was used for each 
experimental condition. Treatment groups consisted of 5 to 15 mice.   
 In vivo infections. An anesthetic cocktail containing xylazine (7.5 mg/ml), 
acepromazine maleate (2.5 mg/ml), and ketamine (37.5 mg/ml) was prepared. 
Approximately 1-µl of cocktail was injected intramuscularly per gram of body 
weight (19). Following anesthesia, one naris was infected with a 5-µl dose of 106 
pfu (~100 LD50s) of wt VACV. Mice were treated 1, 2 or 3 dpi with 102 – 107 pfu 
of treatment virus administered intranasally (IN) into the same naris as the 
challenge virus. Scarification was done as previously described (109). Disease 
symptoms and animals’ health were monitored every other day for the length of 
the experiment. The IACUC protocol number 08-970R was followed. 
 Weight loss. Weight loss was determined by weighing each mouse on 
alternate days. The percent weight gain or loss was determined and animals that 
lost more than 30% of their original body weight were euthanized and considered 
dead from the challenge.   
Sickness index. A relative sickness index that takes into consideration 
typical symptoms of a wt VACV infection was created. Each animal from each 
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group was assigned an arbitrary score (1-4) based on the severity of the following 
symptoms: ruffled fur, lack of activity, breathing difficulty, eye infection, 
hunching and weight loss. This index also takes into consideration the number of 
animals euthanized within each group (each death accounts for a value of 0.8 in 
the death/life score, if all animals in the group die, the line stops).   
 Tissue distribution. Animals were infected IN with 106 pfu of wt VACV 
(Day 0) and treated with 107 pfu of v50ΔB13RMγ. On alternate days beginning 
with 2 dpi, three animals were euthanized and then immediately dissected. The 
organs removed (nasal cavity, brain, lungs, heart, liver, spleen, kidney and 
ovaries) were immediately frozen in liquid nitrogen and then stored at -80˚C. A 
10% homogenate was prepared for each organ by adding 1 mM Tris pH 8.8 with 
gentamycin. All tissues with the exception of the nasal cavity were then 
homogenized using a PCR tissue homogenizing kit (Fisher). The nasal cavity was 
homogenized using a Mixer Miller 301 device (Retsch). All homogenates were 
subjected to three rounds of freezing (-80°C)-thawing for 30 minutes on ice and 
then quick thawing (37°C). After three rounds of freezing-thawing, samples were 
subjected to a 7-minute spin using a tabletop centrifuge at 700 x g at 4˚C to 
remove all cell debris. After centrifugation, supernatants were retained and 
dilutions were performed for plaque assays on RK13 cells.   
Viral loads for tissue distribution were conducted in triplicate by infecting 
monolayers of RK13 cells. Twenty-four hours post-infection, two replicas were 
stained with crystal violet to determine the viral load within the tissue (pfu per 
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gram of tissue). Differentiation of wt VACV and the treatment v50ΔB13RMγ 
virus was done by overlaying the third replica with 1% agarose, MEM 5% FBS 
and 400 µg/ml X-Gal (5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside). The 
v50ΔB13RMγ could be identified due to the fact that this virus expresses lacZ at 
the B13R site.  
 Immunohistochemistry. Tissues were perfused with phosphate-buffered 
saline (PBS) via cardiac perfusion followed by fixation with 10% formalin. After 
the soft tissue was removed the skull was decalcified using EGTA. The skull was 
embedded in paraffin and sliced at 3-µm thickness using a microtome. 
Deparaffinized tissue sections of the nose were incubated with 2% H2O2 in 
methanol for 10 minutes to quench endogenous peroxidases and then rinsed in 
PBS. Detection of VACV antigen was done using rabbit anti-VACV and the 
VECTASTAIN Elite ABC kit (Rabbit IgG) from VECTOR Laboratories 
following the manufacturer's protocol. 
 Data analysis. Errors band indicate standard error of the mean. Survival 
analysis was done using Kaplan-Meier curves and the log-rank test analyses were 
performed using the statistical software program GraphPad Prism (version 5.0c 
for Macintosh). 
 
RESULTS 
 v50ΔB13RMγ causes weight recovery and protects mice from death. 
The WR strain of VACV was originally derived from serial passages in mouse 
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brain and thus is a neurotropic, highly virulent strain of VACV (111). Several 
VACV WR mutants of E3L (an IFN antagonist protein) as well as VACV WR 
recombinants expressing either muIL-18 or muIFN-γ were tested for their ability 
to confer post-exposure prophylaxis in mice upon challenge with a lethal dose of 
VACV WR. The VACV E3L mutants chosen for this study have previously been 
shown to have reduced pathogenesis and neurovirulence phenotypes in mice (19). 
Similarly, IL-18 was selected due to its pro-inflammatory properties, ability to 
induce synthesis of IFN-γ, activation of NK cells and its main role in the T-
lymphocyte helper type 1 response (242). IFN-γ was chosen due to its multiple 
immune stimulatory effects on macrophage activities, NK cell cytolysis, and T 
and B cell responses (140, 163, 166, 190, 210). 
IN infections of C57BL/6 mice were performed with ~100 LD50s wt 
VACV as described in the materials and methods section. Animals were then 
treated 1 dpi with 107 pfu of the mutant or recombinant virus (Fig. 1). As shown 
in Fig. 2, all animals lost weight to day 6 post infection, but only mice treated 
with v50ΔB13RMγ recovered. Fig. 3 shows the survival rate for each of the 
mutants tested. Treatment with v50ΔB13RMIL-18 resulted in 60% survival 
(P<0.005, log-rank test) while 30% survival was observed when animals were 
treated with either VACVΔE3L, VACVE3LΔ7C or VACVE3L::ATVeIF2α 
(P>0.05, log-rank test) and 20% survival when treated with VACVE3LΔ26C 
(P<0.05, log-rank test). Only treatment with v50ΔB13RMγ was able to confer 
100% survival (P<0.0001, log-rank test). Partial protection was seen with doses 
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as low as 105 pfu, while full protection in the animals required treatment with 107 
pfu (Fig. 5).  
The parental virus of  v50ΔB13RMγ, v50ΔB13R, was also evaluated in 
order to determine if the deletion of the serpin gene B13R was responsible for the 
protection. B13R is nonessential for VACV replication, and deletion from the 
virus results in reduced replication and pathogenesis in mice (137). Treatment of 
mice infected with wt VACV as described above with the parental virus 
(v50ΔB13R) was analyzed. This virus did not provide protection against infection 
with VACV with only 17% surviving (Fig. 6, P>0.5, log-rank test), suggesting 
that expression of IFN-γ and not the deletion of B13R, is responsible for the 
survival of the mice. 
 Post-exposure prophylaxis with v50ΔB13RMγ is more effective when 
administered one day post-infection. In order to determine the temporal 
requirements of protection, animals were infected with 106 pfu (~100 LD50s) of wt 
VACV and then treated with 107 pfu of v50ΔB13RMγ at 1, 2, or 3 dpi. Animals 
showed 100% survival when treated 1 dpi, while all mock-treated animals died by 
day 8 (P<0.005, log-rank test). Protection was reduced to 40% (P<0.05, log-rank 
test) when treatment virus was administered at 2 dpi, and to 20% (P>0.05, log-
rank test) when animals were treated at 3 dpi (Fig. 7A). Additionally, when 
animals were initially infected with ten-fold more wt VACV (107 pfu or 1000 
LD50s) followed by treatment 1 dpi with v50ΔB13RMγ a slight decrease to 80% 
survival was observed (P<0.005, log-rank test).   
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A relative sickness index with values from 0 to 4 was created as indicated 
in the materials and methods section. Animals that were untreated reached a 
relative sickness index of 2.7 by 6 dpi and succumbed to the infection by 8 dpi.  
However, mice that were treated with 107 pfu v50ΔB13RMγ at 1 dpi reached a 
maximum relative sickness of 0.86 by 6 dpi. By day 18, these mice attained 
weights that were comparable to the mock-infected mice and had a relative 
sickness index of 0. Interestingly, animals that were treated either 2 or 3 dpi 
showed similar morbidity and had a sickness index similar to that of the untreated 
animals at 8 dpi, (2.5 versus 2.66). When animals were infected with 107 pfu of 
wt VACV and treated 1 dpi, they reached a maximum score of 1.14 by 8 dpi and 
the animals that survived showed a slightly delayed recovery as compared to mice 
infected with 106 pfu wt VACV and treated 1 dpi (Fig. 7B). 
 The intranasal route of administration of post-exposure prophylaxis 
with v50ΔB13RMγ  is most effective. In the previous experiments, all viral 
infections were administered into the same naris of the animal. Since the current 
smallpox vaccine is given by scarification and several vaccines are administered 
by intramuscular (IM) injection, animals were challenged IN as described above 
and treated with v50ΔB13RMγ into the opposite naris (INON), by scarification 
(SC) and by IM injection. The results show that 100% protection occurred only 
when the treatment was given into the same naris as the challenge virus (Fig. 8A).  
On the other hand, mice that remain untreated had marked weight loss, morbidity 
and died 8 dpi. INON treatment resulted in 40% survival (P<0.005, log-rank test), 
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and IM or SC treatment resulted in 20% and 15% survival, respectively (P>0.5, 
log-rank test) (Fig. 8A). As in previous experiments, a relative sickness index was 
generated. Animals that were treated within the same naris had the lowest relative 
sickness index, 0.6 at 8 dpi, while treatment in the opposite naris had an index of 
1.74 and treatment via SCA or IM injection had the highest sickness index of 2.0 
by 8 dpi, similar to untreated animals (Fig. 8B).   
 Viral spread of wt VACV was similar in untreated and treated 
animals. IFN-γ is both an effective antiviral as well as a modulator of the innate 
immune response by leading to the activation of macrophages, neutrophils and to 
increased expression of MHC class I and II proteins (140, 163), which could limit 
the spread of VACV, and lead to protection against mortality. To determine the 
kinetics of replication and viral spread, various mouse tissues (nasal cavity, brain, 
lungs, heart, liver, spleen, kidney and ovaries) were examined. At 2 dpi wt VACV 
was observed in the nose, brain, lungs and spleen of mock-treated animals (Fig. 
9). Animals that were treated with v50ΔB13RMγ showed similar viral loads in the 
nose, brain and spleen as in untreated animals, but no virus was detected in the 
lungs (Fig 9). By 4 dpi wt VACV was detected in all of the organs examined with 
similar titers in most tissues in both untreated and treated animals (Fig. 9 and data 
not shown). However, at 4 dpi titers in the brain of treated animals were two logs 
lower than titers in the brain of untreated mice (Fig. 9), while titers in the ovaries 
of treated mice were two logs higher than in untreated mice (data not shown). By 
6 dpi, viral loads in treated animals peaked within the nose, brain, heart, and lungs 
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and reached titers close to those observed in untreated animals at 4 dpi (Fig. 9 and 
data not shown). By 10 dpi VACV could only be detected in the nose, brain, and 
lungs indicating that the treated animals were effectively clearing the viral load 
(Fig. 9). X-gal staining was done in order to differentiate v50ΔB13RMγ from 
wild-type virus. Examination of the different tissues revealed low level replication 
of this virus in the nose (4-8 dpi) and brain (2 and 6 dpi), as well as detection in 
the heart and lungs of one animal at 6 and 8 dpi respectively. These results are 
similar to viral loads in tissues from mice infected with 107 pfu of v50ΔB13RMγ 
alone (Fig. 10 and data not shown). 
 Animals treated with v50DB13RMγ show decreased tissue necrosis, 
edema, and epithelial sloughing into the nasal cavity. Histological analyses of 
nasal tissues (Fig. 11) were performed in order to determine differences in 
pathology following treatment with v50ΔB13RMγ (Fig. 12). Staining for VACV 
antigen showed that in a wt VACV infection followed by mock treatment, virus 
replicated in the epithelial cell layer early during infection at day 3. As infection 
progressed, VACV replication moved into the underlying lamina propria and 
epithelial sloughing, tissue necrosis, and edema were evident (Fig. 13). By 8 dpi 
in an untreated animal, it could be observed that the nasal cavity was unilaterally 
blocked and replication had progressed in both dorsal and lateral directions (Fig. 
14). In animals treated with v50ΔB13RMγ, VACV staining was observed at day 3 
in the epithelial cell layer, however at days 5 and 8, a reduced progression of 
VACV staining into the lamina propria was observed as well as reduced levels of 
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tissue necrosis and edema (Fig. 13). At 8 dpi in treated animals VACV replication 
was evident along the airway epithelium but did not progress laterally (Fig. 14).  
 
DISCUSSION 
In this chapter a recombinant VACV that expresses IFNγ, v50ΔB13RMγ, 
was found to be the best post-exposure prophylaxis candidate in a VACV-WR 
animal model and results indicate that this recombinant virus may be eliciting an 
immunoregulatory rather than an antiviral effect when used as a treatment.  
There are currently anecdotal studies regarding the efficacy of post-
exposure vaccination protection of individuals when administered up to 4 days 
post-exposure (157). The present work was intended to evaluate potential vaccine 
candidates for prophylaxis after post-exposure to a pathogenic orthopoxvirus. 
While other post-exposure prophylaxis studies have been done using replication-
deficient and replication-competent VACV vaccine strains in order to protect 
against a lethal infection with VACV-WR or ECTV (168, 173, 221), to current 
knowledge this study is the only one that successfully uses a recombinant VACV 
expressing IFN-γ, v50ΔB13RMγ, for post-exposure protection.  
The present results demonstrate that IFN-γ is not acting as an antiviral as it 
was observed that viral replication in different organs analyzed is similar between 
animals infected with wt VACV and animals infected with wt VACV but treated 
1 dpi. Moreover, several parameters were studied in order to optimize post-
exposure protection in our animal model. Intranasal infection was chosen as the 
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route of challenge as this is considered to be the natural route of transmission for 
smallpox (174). In this VACV-WR post-exposure model, the route of treatment 
was important being IN treatment the most effective as survival rate of animals 
infected IN with wt VACV and treated with v50ΔB13RMγ, especially into the 
same naris as challenge, provided complete protection. The use of other routes of 
treatment reduced the survival rate to 40% (INON) and 20% (IM and SCA) (Fig. 
8A).  Similarly, in a study by Staib et al. (221), mice infected IN with 5 x 104 pfu 
(1 LD50) VACV-WR strain and then treated IM at 1, 2, 3 or 4 dpi with 108 
infectious units of the modified VACV Ankara (MVA) died by day 9 and had no 
effect compared with mock-vaccinated animals. Mice infected IN with 106 pfu 
VACV-WR and treated by scarification with 106 pfu VACV Elstree strain 
presented similar results (221). The fact that in the model treatment is more 
effective when administered in the same site of the infection could be explained in 
part by the low replication levels of v50ΔB13RMγ in the tissues examined (Fig. 
10). Despite its low levels of replication in animal models, v50ΔB13RMγ is 
known to elicit potent humoral, T helper and cytotoxic T cell immune responses 
suggesting that the efficacy of this recombinant VACV is not compromised (136).  
Another parameter that was examined was time of post-exposure 
treatment. Results have shown that post-exposure immunization with 
v50ΔB13RMγ is more effective in protecting mice against a lethal infection with 
VACV-WR when administered one day post-infection (Fig. 7). Other studies have 
proven that post-exposure protection against a challenge dose of 1 to 3 LD50s is 
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possible when treatment with MVA is applied the same day of infection (221). 
The action of IFN-γ by itself has been proven to be effective against a challenge 
dose of 8 LD50s when treatment was administered one day before or the same day 
of infection and using a total of five consecutive doses of IFN-γ with treatments 
that were started at 1, 2, and 3 dpi, resulting in 90, 70, and 50% survival rates 
respectively (140). In contrast, the present results show the efficacy of 
v50ΔB13RMγ for post-exposure vaccination prophylaxis following higher 
challenge doses of 100 LD50s of VACV-WR with 100, 40 and 20% survival when 
treatment was administered at 1, 2 or 3 dpi respectively and 80% when mice were 
challenge with 1000 LD50s  and treated 1 dpi (Fig. 7). Moreover, the effectiveness 
of IN vaccination was dependent on both the dose of v50ΔB13RMγ and on 
expression of IFN-γ as treatment with the parental virus v50ΔB13R, only 
provided 17% efficacy in this model (Fig. 6).  
Although v50ΔB13RMγ does not spread well in tissues, it replicates to 
low levels in the nose of treated animals (Fig. 10), which could contribute to an 
increase in the effectiveness of the prophylactic treatment. Additionally, murine 
IFN-γ has a low affinity for the VACV-expressed IFN-γ binding protein (IFN-γ 
BP) (3), making its availability higher when used for treatment of a VACV-WR 
infection.   
Despite seeing less morbidity and no mortality in the treated animals with 
v50ΔB13RMγ, viral replication was observed in the organs that were examined.  
One of the morbidity symptoms that was evaluated was weight loss which has 
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been correlated with fever and is a reliable method of determining relative 
pathogenesis (16). This study shows a continual weight loss in animals infected 
with wt VACV. However, animals treated with v50ΔB13RMγ lose a maximum of 
25% weight and recover rapidly (Fig. 7B) reaching a weight comparable to 
uninfected animals by day 18 (data not shown). While data show that viral load 
and tissue distribution were similar for both untreated and treated groups up to 6 
dpi, most mice infected with wt VACV did not survive to day 8 (Fig. 9 and data 
not shown). In this study, viral titers in all the affected organs from treated 
animals diminished after day 6 and by day 10 wt VACV is only found in nose, 
brain and lungs (Fig. 9). Viral replication of wt VACV in the nose, brain, lungs, 
ovary, spleen and liver has been previously observed in other studies (19, 87, 
173). Immunohistochemistry results in this post-exposure VACV model showed 
less necrosis and edema blocking the air passage in all of the animals that were 
treated with v50ΔB13RMγ as compared to the mock-treated animals (Figs. 12 and 
13).  
Treatment with a similar recombinant virus, v50ΔB13RMIL-18, which 
expresses IL-18 (an IFN-γ inducing factor), was partially successful in protecting 
mice from death and the viral spread to tissues was similar to wt VACV (data not 
shown). This partial protection could be due to the fact that VACV expresses an 
IL-18  binding protein, which binds IL-18 tightly (192, 224).  
Altogether these results suggest that post-exposure treatment in the 
VACV-WR model has more efficacy when administered in the same site of 
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infection and that the expression of IFN-γ is more effective than treatment with 
conventional vaccine strains.  
Because IN vaccination with v50ΔB13RMγ was shown to prevent death in 
mice infected with wt VACV in this VACV-WR model, a parallel study was 
performed by Dr. R. Mark Buller's group in order to determine the efficacy of 
post-exposure protection in a mousepox model which has been useful for testing 
both antivirals and vaccines (24). In this study A/Ncr and C57BL/6 mice were 
challenged IN with a lethal dose of ECTV. Opposite to what was observed in the 
VACV-WR model, IN treatment with v50ΔB13RMγ was unable to prevent 
mortality in A/Ncr and C57BL/6 mice and all animals died by day 10. The 
footpad route was then chosen as the route of treatment as this mimics natural 
ECTV infection in an experimental setting (59). Interestingly in this ECTV 
model, survival was 83.3% when animals were treated 1 dpi with v50ΔB13RMγ, 
and a 50% survival was observed when vaccinating with the parental v50ΔB13R. 
Previous results have demonstrated that post-exposure protection against ECTV 
was dose and time dependent with a similar 83% of mice protected at 1 dpi 
following ID vaccination with VACV Lister (173).  
Differences between the VACV and the ECTV model may be due to the 
events following infection using different routes of inoculation as well as disease 
progression. Such differences have been previously reported in an ECTV 
infection model (59, 65, 173). Moreover, failure to protect infected mice could be 
attributed to the fact that the IFN-γ BP expressed by ECTV has been shown to 
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inhibit the biological activity of murine IFN-γ while the IFN-γ BP expressed by 
VACV has low binding affinity for murine IFN-γ (161, 207, 220).   
Overall the results presented in this chapter indicate that v50ΔB13RMγ is 
likely not working as an antiviral but as a stimulator and modulator of the immune 
responses. IFN-γ is known to mediate several immune responses including 
activation of macrophages and neutrophils, enhancement of the NK cell activity, 
regulation of B cell functions, stimulation of specific cytotoxic T cell immunity, 
chemokine gene expression, increase in expression of MHC class I and II 
proteins, leukocyte attraction to the site of infection as well as contributing to the 
growth, maturation and differentiation of many cell types (140, 163, 166, 190, 
210). While v50ΔB13RMγ is a highly attenuated virus, it is still able to induce 
humoral and cell-mediated immune responses (136). A possible mechanism of 
action will be that following infection with VACV, v50ΔB13RMγ infects cells 
and initiates a rapid Th1 response at the site of infection, which includes 
macrophage activation, complement binding and opsonizing antibodies and 
neutrophil activation for enhanced microbial killing. This rapid response would 
have a "delay" effect on the infection giving the animal time to mount a more 
robust immune response against VACV. Further studies are necessary in order to 
determine the immunological mechanisms involved in this process and which 
cells are the key players.  
 This work suggests that expression of murine IFN-γ by a recombinant 
VACV is able to confer reduction in pathogenesis and prevent mortality in mice 
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infected with a lethal dose of wt VACV. These results highlight the importance of 
IFN-γ as a modulator of the immune response for post-exposure prophylaxis. 
Immunization with a recombinant virus expressing IFN-γ is known to prevent 
viremia and death (140, 190) as well as promote a potent immune response (136).  
Thus, the use of v50ΔB13RMγ could be an effective way to optimize post-
exposure prophylaxis against smallpox and other orthopoxviruses infections. 
Moreover, together with ST-246, cidofovir and VIGIV, a recombinant VACV 
expressing IFN-γ could be utilized as another tool for post-exposure prophylaxis 
treatment. 
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FIG. 1. Study design. Groups of 5 to 10 four-week-old C57BL/6 mice were 
infected intranasally with 106 pfu (~100 LD50s) of wt VACV and treated one day 
post-infection with 107 pfu of VACVE3LΔ7C, VACVE3LΔ26C, VACVΔE3L, 
VACVΔE3L::ATVeIF2α, v50ΔB13RMγ and v50ΔB13RMIL-18. There were two 
groups of control animals, one group was infected with wt VACV and was mock-
treated, and the second group of animals was mock-infected and mock-treated.  
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FIG. 2. Weight change after intranasal infection with a lethal dose of wt VACV 
and subsequent treatment with different VACV mutants. Groups of 5 to 10 four-
week-old C57BL/6 mice were infected intranasally with 106 pfu (~100 LD50s) of 
wt VACV and treated one day post-infection with 107 pfu of VACVE3LΔ7C (○), 
VACVE3LΔ26C (●), VACVΔE3L (♦), VACVΔE3L::ATVeIF2α (□), 
v50ΔB13RMγ (▲) and v50ΔB13RMIL-18 (∆). There were two groups of control 
animals, one group was infected with wt VACV alone and was mock-treated (■), 
the second group of animals was mock-infected and mock-treated (◊). Each 
mouse was weighed at the indicated times. Average percentage of initial weight 
of the animals infected with each virus is plotted versus time (days post-
infection). Lines ending prematurely indicate mortality. Error bars indicate the 
standard error of the mean.   
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FIG. 3. Survival curve after intranasal infection with a lethal dose of wt VACV 
and subsequent treatment with different VACV mutants. The data represent a pool 
of two independent experiments using group sizes of 5 mice.  Groups of 5 to 10 
four-week-old C57BL/6 mice were infected intranasally with 106 pfu (~100 
LD50s) of wt VACV and treated one day post-infection with 107 pfu of 
VACVE3LΔ7C (○), VACVE3LΔ26C (●), VACVΔE3L (♦), 
VACVΔE3L::ATVeIF2α (□), v50ΔB13RMγ (▲) and v50ΔB13RMIL-18 (∆). 
There were two groups of control animals, one group was infected with wt VACV 
and was mock-treated (■), the second group of animals was mock-infected and 
mock-treated (◊).  
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FIG. 4. Schematic representation of v50ΔB13RMγ B13R locus. The xanthine-
guanine phosphorybosyltransferase (gpt) gene and the murine IFN-γ gene are 
under of the two back-to-back synthetic VACV promoters (dsP). The lacZ marker 
gene is under the P11 promoter. Position of the genes was obtained through DNA 
sequencing. 
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FIG. 5. v50ΔB13RMγ dose response. Groups of 10 four-week-old C57BL/6 mice 
were infected intranasally with 106 pfu (~100 LD50s) and treated one day post-
infection with doses of 102, 103, 104, 105, 106, 107 and 5 x 108 pfu of 
v50ΔB13RMγ (▲).   
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FIG. 6. Survival curve after intranasal infection with a lethal dose of wt VACV 
and subsequent treatment with the parental virus v50ΔB13R. Groups of 5 four-
week-old C57BL/6 mice were infected intranasally with 106 pfu (~100 LD50s) of 
wt VACV and treated one day post-infection with 107 pfu of v50ΔB13R (●), and 
v50ΔB13RMγ (▲). There were two groups of control animals, one group was 
infected with wt VACV alone and was mock-treated (■), the second group of 
animals was mock-infected and mock-treated (◊).  
 
 
 
 
**P<0.005 
P>0.5 
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FIG. 7. Protection of wt VACV infected animals by post-exposure vaccination 
with v50ΔB13RMγ at one, two or three days post-infection. Groups of 5 to 10 
C57BL/6 mice were infected intranasally with 106 pfu (~100 LD50s) wt VACV. 
Animals were treated with 107 pfu of v50ΔB13RMγ at one (▲), two (●) or three 
(♦) days post-infection.  One group was infected with 107 pfu (~1000 LD50s) wt 
VACV and treated with 107 pfu of v50ΔB13RMγ 1 dpi (∆). As controls, animals 
were mock-treated (■), or mock-infected and mock-treated (◊). (A) Comparison 
of survival curves was done using the log-rank test. (B) The graph indicates the 
relative sickness of each group during the course of the infection. Lines ending 
prematurely indicate death of all the animals from the group. A value of 0 
indicates that all the animals from that group were healthy. 
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FIG. 8. Post-exposure protection of wt VACV infected animals treated with 
v50ΔB13RMγ using different routes of treatment. Groups of 12 to 15 C57BL/6 
mice were infected intranasally with 106 pfu of wt VACV. Animals were treated 
one day post-infection with 107 pfu of v50ΔB13RMγ intranasally, IN (▲), 
intranasally using the other nostril, INON (∆), intramuscularly, IM (○) or via 
scarification, SCA (●). One group of animals was infected with wt VACV and 
then mock-treated (■), another group was mock-infected and mock-treated (◊). 
(A) Comparison of survival curves was done using the log-rank test. (B) The 
graph indicates the relative sickness of each group of animals during the course of 
the infection. Lines ending prematurely indicate death of all the animals from the 
group. A value of 0 indicates that all the animals from that group were healthy. 
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FIG. 9. Viral spread of wt VACV in infected animals. Groups of 3 C57BL/6 mice 
were infected intranasally with 106 pfu of wt VACV. Animals remained untreated 
or were treated one day post-infection with 107 pfu of v50ΔB13RMγ. Error bars 
indicate the standard error of the mean. Data represent two independent 
experiments.    
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FIG. 10. Viral spread of v50ΔB13RMγ in infected animals. Groups of 3 C57BL/6 
mice were infected intranasally with 106 pfu of wt VACV. Animals were treated 
one day post-infection with 107 pfu of v50ΔB13RMγ. Replication of 
v50ΔB13RMγ in the tissues from the treated group was examined by X-gal 
staining. Animals infected with 107 pfu of v50ΔB13RMγ. Error bars indicate the 
standard error of the mean. Data represent two independent experiments.    
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FIG. 11. Cross-section of the nose of an uninfected mouse at 2mm depth. 
Structures and type of epithelium found at this depth are indicated as a reference. 
(H&E staining). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S 
n 
1 
2 
3 
i 
v 
m 
Squamous epithelium  
Respiratory epithelium 
Transitional epithelium  
(1)!  Dorsal meatus 
(2)!  Middle meatus 
(3)!  Ventral meatus 
(i)   Root of the incisor tooth 
(n)  Nasoturbinate 
(m) Maxilloturbinate 
(S)  Septum 
(v)  Vomeronasal organ 
 41 
 
 
 
 
 
 
 
 
 
FIG. 12. Histopathologic comparison and infection progression in the nose 
section. Hematoxylin and eosin staining (H&E). All sections were obtained at 2 
mm depth. S= septum, M=meatus (air passage) and T=Turbinate. 100X 
magnification. 
 
 
 
 
 
 
 
 
 
 
 
Mock / Mock wt / Mock wt / v50!B13RM" 
D
ay
 3
 
S 
T M 
D
ay
 5
 
D
ay
 8
 
S 
 42 
 
 
 
 
 
 
 
 
 
FIG. 13. Histopathologic comparison and infection progression of VACV in the 
maxilloturbinate section. Mice were infected IN with 106 pfu (~100 LD50s) of wt 
VACV and treated one day post-infection with 107 pfu of v50ΔB13RMγ. All 
representative sections were obtained at 2 mm depth and were stained with 
polyclonal antibodies against VACV. S= septum, T=maxilloturbinate, M=meatus 
(air passage). 100X magnification.  
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FIG. 14. VACV replication in the whole nasal cavity section. Mice were infected 
IN with 106 pfu (~100 LD50s) of wt VACV and treated one day post-infection 
with 107 pfu of v50ΔB13RMγ. Mice were sacrificed at 8 days post-infection. 
Sections were obtained at 2 mm depth and were stained with polyclonal 
antibodies against VACV. S= septum, T=maxilloturbinate, M=meatus (air 
passage), V=vomeronasal organ, i=incisor. 10X magnification. Bar=1mm. 
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CHAPTER 2 
MECHANISM OF ACTION OF A VACCINIA VIRUS EXPRESSING 
INTERFERON GAMMA DURING POST-EXPOSURE PROPHYLAXIS 
 
ABSTRACT 
 While there is anecdotal evidence for efficacy of post-exposure 
vaccination against smallpox, this has not been definitively studied in humans. In 
this study the post-exposure prophylaxis phenomenon was analyzed using a 
recombinant vaccinia virus (VACV) that expresses interferon gamma (IFN-γ), 
which we have previously shown to prevent both morbidity and mortality in an 
animal model. Animals were infected intranasally with 100 LD50s of wild-type 
VACV and then treated one day post-infection with a VACV expressing IFN-γ 
(v50ΔB13RMγ) or its parental (v50ΔB13R). Treatment with v50ΔB13RMγ but 
not the parental reduces the viral load in the olfactory bulb by day 6 post-infection 
although the same phenomenon was not observed in the rest of the brain. Nasal 
lavages were collected at different days post-infection and the immune cell 
populations recruited at the site of infection  were analyzed using flow cytometry 
analysis. Results showed that at early times post-treatment the percentages of 
CD8+ cells and CD11b+Gr1+, also known as myeloid derived suppressor cells, 
were increased in the group treated with v50ΔB13RMγ. Preliminary analyses of 
the TH1 and TH2 cytokine levels, showed higher levels of IL-12 and IL-5 in the 
treated group at early time post-infection. Moreover, the induction of the enzyme 
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nitric oxide synthase may be also playing a role during post-exposure prophylaxis. 
Overall, these results indicate that v50ΔB13RMγ may be acting as a regulator of 
the immune response and that this effect is most probably local affecting 
bystander cells at the site of infection. 
 
INTRODUCTION 
Vaccinia virus (VACV) has been used for the worldwide eradication of 
smallpox, a successful campaign led by the World Health Organization (WHO) in 
the 1970s (237). Although the effectiveness of smallpox vaccination as a 
preventive measure has been well documented there is not a lot of information 
regarding its efficacy for post-exposure treatment (157). Several antiviral drugs 
have been developed as alternative post-exposure treatment such as (S)-1-(3-
hydroxy-2-phosphonylmethoxypropyl)-cytosine, more commonly known as 
cidofovir (45, 222). Other alternatives for treatment include vaccine immune 
globulin (VIG) (240) and ST-246, which has shown protection against 
monkeypox (MPXV) in animals models (209) and is regarded as one of the best 
choices as an antipoxviral drug (167, 185, 186, 219, 246). 
While the search for antiviral treatments against, accidental or not, 
exposure to VACV, Variola virus (VARV) or MPXV still continues (222),  the 
use of VACV as a recombinant vector for protein expression, vaccine 
development and even cancer treatment  has also been explored (108, 158, 229). 
Currently, there are two effective recombinant vaccines, one for rabies (175) and 
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the one for rinderpest, a highly contagious disease with 80% fatality (80, 229, 
248). 
Because some complications with VACV have been observed specially in 
immunocompromised and immunosupressed people (74), there is a need to 
understand the immune responses upon exposure to the virus. While some 
cytokines such as interleukin 2 (IL-2), tumor necrosis factor alpha (TNF-α) and 
interferon gamma (IFN-γ) have shown to decrease virulence, others including 
interleukin 4 (IL-4) increase virulence and morbidity (70, 163, 191, 212).    
Previous studies have demonstrated that VACV expressing IFN-γ can be 
used as an adjuvant as well as an attenuating agent for the production of live 
vaccines that are both safe and have high efficacy (80, 125). Moreover, 
expression of IFN-γ has also been used to influence the course of bacterial 
infection, were VACV as a vector was more effective than fowlpox (37). Other 
viruses such as bovine herpesvirus-1 (BHV-1) have also been used to express 
IFN-γ and the stability of the BHV-1/IFN-γ virus as well as its 
immunomodulating effects studied upon primary infection and following 
reactivation of a latent infection (188). Moreover, expression of human IFN-γ by 
a simian immunodeficiency virus (SIVHyIFN) has shown reduced viral loads in the 
blood of rhesus macaque monkeys that were infected with virus, even in the 
presence of a progressive deletion of the IFN-γ gene. These results suggest that 
the early immune system activation by SIVHyIFN was able to protect against new 
emerging SIV viruses lacking full expression of the lymphokine (79).  
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Expression of IFN-γ in bacteria has also been studied. Administration of a 
recombinant IFN-γ produced in E. coli at the time of a primary immunization with 
vesicular stomatitis virus glycoprotein (VSV-G) for example, has shown to 
enhance a secondary antibody response even a low doses (5).  
The use of recombinant murine IFN-γ to prevent lethal respiratory VACV 
infection has also been successful (140) although the challenge dose of  VACV 
was significantly lower as the ones used in this study. 
The previous chapter described the use of v50ΔB13RMγ, a recombinant 
VACV expressing IFN-γ (v50ΔB13RMγ), for post-exposure treatment in a 
VACV animal model. This recombinant virus was100% effective in protecting 
mice infected with 100 LD50s of wt VACV when administered 1 dpi reducing the 
morbidity symptoms in the treated animals. Moreover, while deletion of the B13R 
serpin homolog gene attenuates VACV  (136, 137), it is not responsible for 
protecting mice against a lethal dose with VACV as it was noted in Chapter 1. 
While v50ΔB13RMγ replicates to high titers in tissue culture, it is a highly 
attenuated virus and replicates at low levels in tissues of infected animals ((136) 
and data from Chapter 1). IFN-γ is known to regulate the immune system (Fig. 
15) by activating macrophages and neutrophils, enhancing NK cells activity, 
regulating the B and T cell responses to antigens, stimulating specific cytotoxic T 
cells, promoting chemokine expression, as well as contributing to the protection 
against viral pathogenesis (140, 163, 166, 190, 210). Mice bearing a disrupted 
IFN-γ gene have impaired production of macrophage antimicrobial products, 
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reduced major histocompatibility complex (MHC) class II expression and are 
more vulnerable to infections against pathogens such as Mycobacterium bovis 
(42) and Plasmodium falciparum (6). It has also been observed that during a 
VACV infection IFN-γ inhibits VACV replication through the induction of nitric 
oxide synthase (iNOS) in murine macrophages which leads to the production of 
nitric oxide (NO) from the guanidine nitrogen of L-arginine (99). IFN-γ is the 
only known cytokine to induce NOS in macrophages, production of NO in turn 
affects DNA replication of VACV preventing virus particle formation (99, 113).  
The purpose of this chapter is to determine v50ΔB13RMγ mechanism of 
action and the characterization of the immune response following post-exposure 
prophylaxis in a VACV-WR animal model. As noted in Chapter 1, although all 
animals infected with wt VACV  survived upon treatment with v50ΔB13RMγ, 
VACV was found present in all the organs examined suggesting that this virus is 
acting more as an immunoregulator than as an antiviral. Thus, v50ΔB13RMγ 
could be indeed orchestrating some immune responses that could lead to less 
morbidity and 100% mortality in this animal VACV model. 
 
MATERIALS AND METHODS 
 Recombinant viruses. The Western Reserve (WR) strain of VACV was 
used as the parental virus for these studies. The recombinant VACV expressing 
IFN-γ (v50ΔB13RMγ) virus was constructed as previously described (136). This 
virus expresses VSV-G at the TK locus and lacZ, gpt, and murine IFN-γ at the 
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B13R site. Construction of the parental virus (v50ΔB13R) has already been 
described (137).   
Cell culture. Viruses were amplified in Baby Hamster Kidney 21 (BHK) 
cells and partially purified by pelleting through a 36% sucrose pad, as previously 
described in the literature (15, 54). BHK and Rabbit Kidney 13 (RK13) cells were 
cultured in Eagle's Minimal Essential Medium (MEM, Gibco, BRL) containing 
5% fetal bovine serum (FBS, Hyclone), 50 µg/ml of gentamycin, and 0.1 mM 
nonessential amino acid solution (Gibco, BRL) and vitamin supplements. Both 
BHK and RK13 cells were incubated at 37˚C with 5% CO2.   
 Mice. Four-week old female C57BL/6 from Charles River Laboratories 
and NOS2-/- mice (B6.129P2-Nos2tm1Lau/J) from The Jackson Laboratory were 
housed  at the Arizona State University Department of Animal Care and 
Technologies according to IACUC regulations. Each cage contained a maximum 
of 5 mice and a separate cage was used for each experimental condition.  
 In vivo infections. An anesthetic cocktail containing xylazine (7.5 mg/ml), 
acepromazine maleate (2.5 mg/ml), and ketamine (37.5 mg/ml) was prepared. 
Approximately 1-µl of cocktail was injected intramuscularly per gram of body 
weight (19). Following anesthesia, one naris was infected with a 5-µl dose of 106 
pfu (~100 LD50s) of wt VACV. Mice were treated 1 dpi with 107 pfu of treatment 
virus administered intranasally (IN) into the same naris as the challenge virus. 
Disease symptoms and animals’ health were monitored every other day for the 
length of the experiment. The IACUC protocol number 08-970R was followed. 
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 Weight loss. Weight loss was determined by weighing each mouse on 
alternate days. The percent weight gain or loss was determined and animals that 
lost more than 30% of their original body weight were euthanized and considered 
dead from the challenge.   
 Recovery of virus from tissues. Animals were infected IN with 106 pfu 
of wt VACV (Day 0) and treated with 107 pfu of v50ΔB13RMγ or 107 pfu of 
v50ΔB13R at 1 dpi. On days 2 and 6 post-infection, five animals from each group 
were euthanized and then immediately dissected. The olfactory bulb was 
separated from the cerebrum/cerebellum and samples were immediately frozen in 
liquid nitrogen and then stored at -80°C. A 10% homogenate was prepared by 
adding 1 mM Tris pH 8.8 with gentamycin. The tissues were then homogenized 
using a PCR tissue homogenizing kit (Fisher). All homogenates were subjected to 
three rounds of freezing (-80°C)-thawing for 30 minutes on ice and then quick 
thawing (37°C). After three rounds of freezing-thawing, samples were subjected 
to a 7 minute spin using a tabletop centrifuge at 700 x g at 4°C to remove all cell 
debris. After centrifugation, supernatants were retained and dilutions were 
performed for duplicate plaque assays on RK13 cells. Thirty hours post-infection, 
the replicas were stained with crystal violet to determine the viral load within the 
tissue (pfu per gram of tissue).    
 Immunohistochemistry. Tissues were perfused with phosphate-buffered 
saline (PBS) via cardiac perfusion followed by fixation with 10% formalin. After 
the soft tissue was removed the skull was decalcified using ethylene glycol 
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tetraacetic acid (EGTA). The skull was embedded in paraffin and sliced at 3 µm 
thickness using a microtome. Deparaffinized tissue sections of the nose were 
incubated with 2% H2O2 in methanol for 10 minutes to quench endogenous 
peroxidases and then rinsed in PBS. Detection of VACV antigen was done using 
rabbit anti-VACV, VECTASTAIN Elite ABC kit (Rabbit IgG) and the 3,3'-
diaminobenzidine (DAB) Substrate Kit from VECTOR Laboratories following 
the manufacturer's protocol. Detection of neutrophils was done using the rat anti-
mouse neutrophils (MCA771GA, clone 7/4) monoclonal antibody by AbD 
Serotec. Biotinylated anti-rat IgG (mouse absorbed) made in rabbit and the 
VECTOR NovaRED Substrate Kit were used for the detection of neutrophils 
following manufacturer's protocol.   
Harvesting  and processing of sinus lavages. Mice were euthanized by 
intraperitoneal injection and held in the nose-down position. Following 
decapitation, the nasal lavages were done by introducing a single lumen catheter 
connected to the trachea and a lavage of 1 ml of sterile phosphate-buffered saline 
(PBS) with 1% fetal bovine serum (FBS) and collected below the nose.   
Flow cytometry. Samples from the nasal lavages were centrifuged, the 
pellet resuspended, pooled (n=5) and filtered using a 70µm strainer. Following the 
addition of red blood cell lysis buffer, the samples were centrifuges and the pellet 
resuspended in FACS buffer. Cell counts were performed using a 
haemocytometer. Cells were then stained with FITC-conjugated anti-CD49b/Pan-
NK cells (clone DX5), PE-Texas Red conjugated anti-CD45R (clone RA3-6B2), 
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APC conjugated anti-CD3e (clone 145-2C11), PB-conjugated anti-CD4 (clone 
RM4-5), APC-Cy7 conjugated anti-CD8a (clone 53-6.7), PerCP-Cy5.5 
conjugated anti-Cd11b (clone  M1/70), PE-Cy7 conjugated anti-Ly6G/Ly6C 
(clone RB6-8C5 ), PE conjugated anti-Ly6C (clone AL-21, PE-Cy7 anti-Ly6G 
(clone 1A8) or isotype controls using standard techniques. All antibodies and 
isotype controls were purchased from BD Biosciences. Stained cells were 
subsequently analyzed using the FACS Diva software (BD Biosciences). 
 Multiplexed microsphere cytokine immunoassay (Bio-Plex assay). 
Samples from the nasal lavages were collected and treated as above. The 
supernatants were assayed for the presence of cytokines using a multiplexed 
coupled magnetic beads immunoassay customized kit containing the Bio-Plex Pro 
Mouse cytokine TH1/TH2 assay (Bio-Rad, catalog number M60-00003J7) as well 
as detection antibodies for IL-6, IL-12(p40), KC, MIP-1 alpha, MIP-1 beta, 
RANTES and MIP-2, all from Bio-Rad. The assay was done following 
manufacturer's protocol. 
 Data analysis. Errors band indicate the standard error of the mean. 
Survival analyses were done using Kaplan-Meier curves and log-rank test 
analyses. The differences between experimental groups were analyzed using the 
one way ANOVA test. All analyses were performed using the statistical software 
program GraphPad Prism (version 5.0c for Macintosh). 
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RESULTS 
 
 Neutrophil recruitment following intranasal VACV infection. IFN-γ is 
known to activate neutrophils depending on the stimuli and environmental 
conditions (57). Previous studies have shown that recombinant IFN-γ does not 
have a chemotactic effect on neutrophils or macrophages both in vitro or in vivo 
(27) but rather it may act as a signal to allow adherence of neutrophils at the site 
of infection (57). Neutrophils can be observed as early as 3 dpi in both mice 
infected with 100 LD50s of wt VACV and mice that were infected with 100 LD50s 
of wt VACV and treated 1 dpi with 107 pfu of v50ΔB13RMγ (Fig. 16A). By day 
8 post-infection, neutrophils can be clearly observed in areas where VACV is 
present. This is accompanied by tissue destruction, edema and blockage of the air 
passage in mice that were infected but not treated with v50ΔB13RMγ (Fig. 16B). 
 Treatment with v50ΔB13RMγ reduces viral replication in the 
olfactory bulb of animals infected with wt VACV. VACV virus replication has 
previously been detected in the brain from both untreated and treated animals 
(Chapter 1). Because of the importance of the olfactory bulb (Fig. 17) in VACV 
pathogenesis during an intranasal infection, it was required to assess if there was 
any difference in VACV replication between untreated animals and animals 
treated with v50ΔB13RMγ. A histopathologic comparison at 8 dpi showed VACV 
in the olfactory epithelium and the glomerular and outer plexiform layer of the 
olfactory bulb in untreated animals while VACV antigen was only present in the 
olfactory epithelium of treated animals (Figs. 18, 19A and 19B). To further 
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investigate a difference in viral load between animals infected with wt VACV and 
animals treated with either the parental virus v50ΔB13R or v50ΔB13RMγ, both 
the olfactory bulb and the cerebrum/cerebellum regions were harvested at 2 and 6 
dpi. Following homogenization of the samples and three rounds of freeze/thaws, 
viral titers were obtained for each of the samples from each group. A statistical 
significant difference was observed between the viral load in the olfactory bulb of 
the treated group with v50ΔB13RMγ and the untreated group at 6 dpi (Fig. 20A). 
Viral replication of VACV was observed in both untreated and treated groups in 
the olfactory bulb at 2 dpi and in the cerebrum/cerebellum region of the brain at 2 
and 6 dpi (Fig. 20B). 
 Production of nitric oxide (NO) by NOS2 might play a role in post-
exposure prophylaxis. While previous work has provided insight about the 
importance of NO production for the inhibition of VACV replication, all these 
studies required induction by IFN-γ or expression of an iNOS gene in a 
recombinant VACV (99, 113, 152, 200, 201). In Chapter 1 of this dissertation it 
was shown that mice infected 106 pfu of wt VACV and then treated with 107 pfu 
of v50ΔB13RMγ 1 dpi had less morbidity as well as 100% survival. In an attempt 
to determine the importance of NO in the post-exposure prophylaxis model, 
NOS2-/- mice were infected with 102, 104 and 106 pfu of wt VACV and then 
treated 1 dpi with 107 pfu of v50ΔB13RMγ. Infection with 102 pfu of wt VACV 
and treatment with v50ΔB13RMγ did not cause any morbidity and all the animals 
survived (Fig. 21) similar to what is observed in the parental C57/BL6 mice (data 
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not shown). On the other hand, infection  with 104 or 106 pfu of wt VACV and 
treatment with 107 pfu of v50ΔB13RMγ 1 dpi lead to only 60% of survival as 
compared to 100% survival in the parental mice (data not shown and Chapter 1). 
 Proliferation of CD8+ but not CD4+ T cells at 2 dpi in response to 
treatment with v50ΔB13RMγ. It has previously been observed that infection 
with VACV induces a strong CD8+ T cell response in both C57BL/6 and Balb/c 
mice (243) and this response is thought to be the most important response in 
controlling a poxvirus infection (218). In order to evaluate if treatment with a 
recombinant virus that expresses IFNγ promotes the expansion of either CD4+ or 
CD8+ T cells, C57BL/6 mice infected with 106 pfu of VACV were mock-treated 
or treated with 107 pfu of v50ΔB13RMγ 1 dpi. Control animals were either mock-
infected with  or  infected with 106 pfu of wt VACV and mock-treated or treated 
with v50ΔB13RMγ or v50ΔB13R 1 dpi. Nasal lavages were collected at days 2 
and 6 post-infection and analyzed by FACS. CD3+ cells were further analyzed by 
grouping them into CD4+ or CD8+ T cells. At 2 dpi the population of CD8+ T 
cells was higher in the group infected with wt VACV and treated with 
v50ΔB13RMγ compared to the untreated and control groups (Fig. 22). 
 Infection of animals with wt VACV reduces the Gr1+ B220+ cell 
population at the site of infection. While examining the distinct populations of 
immune cells, it was noted a population of Gr1+ B220+ cells in the nasal lavages 
of animals that were mock-infected and then mock-treated 1 dpi as well as in the 
animals that were mock-infected and then treated with 107 pfu of v50ΔB13RMγ 1 
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dpi. This population of cells is not present in either the group that was infected 
with wt VACV and then mock-treated or the group that was infected with wt-
VACV and then treated with 107 pfu of v50ΔB13RMγ 1 dpi (Fig. 23). 
 Increased amount of the myeloid derived suppressor cells population 
(Gr1+CD11b+) at early time post-infection in animals treated with 
v50ΔB13RMγ. While no significant differences were found in the nasal lavages 
from untreated or treated animals in the population of CD49+ (NK) cells (Fig. 24), 
a greater number of GR1+CD11b+ cells was observed at 2 dpi in the group of 
animals that were infected with 106 pfu wt VACV and then treated with 
v50ΔB13RMγ (Fig. 25). By day 6 post-infection the percentages of Gr1+Cd11b+ 
cells were similar in both untreated and treated groups. These Gr1+Cd11b+ cells, 
also known as myeloid derived suppressor cells (MDSCs), have been previously 
described in the literature as a heterogeneous population that includes myeloid 
progenitor cells and immature macrophages, granulocytes and dendritic cells (75).  
 Analysis of the TH1 cytokines show an increase of IL-12 at early times 
post-infection in mice treated with v50ΔB13RMγ. TH1 and TH2 cytokines (Fig. 
26) were examined using the supernatants of the nasal lavage samples from mice 
that were either mock-infected and mock-treated or infected with wt VACV and 
either mock-treated or treated with v50ΔB13RMγ as previously described. 
Analysis of the TH1 cytokines revealed no major differences in the levels of IFN-γ 
and TNF-α while IL-2 levels were undetectable in all the groups examined. On 
the other hand, IL-12 levels were statistically significant (P<0.01) at 2 dpi when 
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compared with the mock-infected/mock-treated group. Levels of IL-12 were 
similar among all groups at 4 and 6 dpi (Fig. 27). 
 TH2 cytokine, IL-5,  increases at early times post-infection in mice 
treated with v50ΔB13RMγ while IL-10 is upregulated at late-times post-
infection in both untreated and treated groups. While levels of IL-4 were 
undetected in all the samples analyzed, analysis of the other TH2 cytokines in the 
post-exposure prophylaxis model revealed increased levels of IL-5 in the mice 
treated with v50ΔB13RMγ at 2 dpi. IL-5 levels were statistically significant  
(P<0.01) when compared with the mock-infected/mock-treated group and the 
group that was mock-infected and then treated with v50ΔB13RMγ at 1 dpi. At 6 
dpi, high IL-10 levels were observed in both untreated and treated groups in 
comparison with the mock-infected/mock-treated group and the group that was 
mock-infected and then treated with v50ΔB13RMγ at 1 dpi (P<0.001) (Fig. 28).  
 Higher levels of chemoattractants are observed in both untreated and 
treated groups at 6 dpi. The supernatants of the nasal lavages were also analyzed 
for the expression of chemoattractants using the Bio-Plex assay. By 6 dpi, levels 
of the macrophage inflammatory protein (MIP) 1 and 2 as well as the regulated 
upon activation, normal T cell expressed (RANTES) protein were higher in both 
the wt VACV infected/untreated group and the group treated with v50ΔB13RMγ 
than the levels in the mock-infected/mock-treated group or the mock-
infected/v50ΔB13RMγ treated group (P<0.01 to P<0.0001) (Fig. 29).  
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 Higher levels of IL-6 at early times post-infection in mice infected 
with wt VACV and then treated 1 dpi with v50ΔB13RMγ. When analyzing the 
levels of IL-6 in the different groups, higher levels were noted at 2 dpi in the 
group that was infected with wt VACV and then treated with v50ΔB13RMγ at 1 
dpi as compared with the mock-infected/mock-treated group (P<0.05). Levels of 
IL-6 were similar among all groups at days 4 and 6 post-infection (Fig. 29). 
 
DISCUSSION 
 In this chapter the mechanism of action of v50ΔB13RMγ as a post-
exposure prophylaxis agent was fruther evaluated regarding its role in the spread 
of VACV to the central nervous system, recruitment of immune cells to the site of 
infection and the secretion of signaling molecules.  
 The use of cytokines as tools for modulating the immune response in 
VACV has been widely study in different systems (136, 140, 191, 212). Of these 
cytokines, IFN-γ has been shown to be an effective adjuvant leading to both 
potent humoral and cell-mediated immunological response (5, 136). IFN-γ is an 
inducible cytokine that plays a very important role in inhibiting virus replication 
and possess a diverse array of physiological activities (214). This cytokine is 
synthesized by CD4+ TH1 cells, CD8+ T cells and NK cells following a response 
to antigens or mitogens (125, 214) and plays and has a key role in both innate and 
adaptive immune responses (210, 214).  
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 Following the discovery of v50ΔB13RMγ as the best candidate for post-
exposure prophylaxis in a VACV-WR model, the next step was to elucidate how 
this recombinant VACV regulates the immune response. Previous studies by 
Kohonen-Corish et al., have shown that expression of IFN-γ in VACV promotes 
recovery from infection in both normal and immunodeficient athymic nude mice 
with an accompanying reduced viral replication indicating that expression of IFN-
γ causes attenuation and pathogenicity reduction in the animal model (125). While 
Kohonen-Corish et al. study was done by expressing IFN-γ in the TK locus, 
similar results were observed when expression of murine IFN-γ was done in the 
B13R locus (136). Moreover, expression of IFN-γ in other viruses such as the 
Simian immunodeficiency virus has also led to an increased attenuation (79). 
 While research on IFN-γ has focused primarily on its interaction with cells 
of the secondary immune response, the role of IFN-γ as a modulator of the innate 
immune response has been overseen (57). Because inflammation usually follows 
a VACV infection, immunohistochemistry of the nose section was used to 
compared if there were any differences in the amount of neutrophils, the major 
cell type mediating acute inflammatory responses (2), recruited to the site of 
infection. By 3 dpi neutrophils are present and associated with both VACV-
infected respiratory epithelium covering the septum and the transitional 
epithelium surrounding the maxilloturbinate. By 8 dpi, less tissue destruction and 
edema can be clearly observed in the representative histological sample from the 
treated group as compared with the sample from the mouse that was infected with 
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wt VACV but remained untreated. These results indicate that neutrophils are 
recruited at the site of infection following wt VACV infection intranasally 
although the potential role of v50ΔB13RMγ in the infected tissue still remains to 
be elucidated as IFN-γ has been shown to alter neutrophil function by activation 
of signaling pathways that use Ca2+ and regulation of gene expression including 
MHC II, chemokines and surfaces markers (57). Moreover, IFN-γ can act as a 
priming agent preparing neutrophils for enhanced activity upon secondary 
stimulation as well as induce the production in neutrophils of nitric oxide (NO) 
via the inducible nitric oxide synthase (iNOS) enzyme (57, 150, 233, 245).  
 Because replication of VACV in the central nervous system can lead to the 
a severe form of encephalitis in humans (76) and neurovirulence in mice (18), the 
next step was to determine if treatment with v50ΔB13RMγ has an effect in the 
viral invasion of the central nervous system. Different studies have shown how 
some viruses enter the central nervous systems following intranasal inoculation. 
Among these viruses are the vesicular stomatitis virus, rabies virus, mouse 
hepatitis virus and herpes simplex virus type 1 as well as cowpox virus (146, 
180). The mechanism how these viruses invade the central nervous system varies 
as they can enter via the olfactory nerve, which connects to the olfactory bulb, via 
the trigeminal system or both (180). In the case of VACV this mechanism has not 
been completely elucidated. Poxvirus replication in the olfactory bulb has 
previously been observed at 6 hours post-infection following intranasal 
inoculation of MVA in C57BL/6 mice (189), intranasal inoculation with cowpox 
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virus in BALB/c mice (146) as well as in ex vivo experiments using VACV vsC9, 
encoding the β-gal gene under control of the VACV TK early promoter (21). 
Recent data from our lab have shown blood brain barrier (BBB) permeability in 
mice infected intranasally with wt VACV (Dr. Karen Denzler, unpublished data) 
while others have shown that the integrity of the BBB plays a important role in 
post-vaccinal encephalitis (76). Infection of the glomerular layer and the outer 
plexiform layer of the olfactory bulb can be clearly observed in a representative 
sample from a group of mice that were infected with wt VACV but remained 
untreated in comparison with the v50ΔB13RMγ treated sample (Fig. 19). These 
results correlate with the viral load observed in the olfactory bulb of the treated 
group as compared with the untreated (Fig. 20). While there was a difference 
between the olfactory bulbs of both groups, the viral load of the cerebrum/ 
cerebellum was similar in both. These results suggest that v50ΔB13RMγ could be 
delaying infection of the olfactory bulb while there could be another mechanism 
by which VACV enters the cerebrum/cerebellum region possibly with the 
participation of nonneuronal cells. This was further supported by preliminary data 
following bilateral bulbectomy, in which depletion of the olfactory bulb delayed 
but did not prevent death of mice infected with wt VACV (data not shown). 
 To further characterize the role of IFN-γ in the post-exposure prophylaxis 
model, iNOS, one of the more characterized IFN-γ inducible genes, was analyzed 
using iNOS knock-out mice (NOS2-/-). The present results show a partial effect 
of v50ΔB13RMγ in the survival of the mice which would indicate that iNOS is 
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required but not necessary for survival in the post-exposure prophylaxis model. 
These results correlate with other studies that have shown that treatment of mice 
with NG-methyl-L-arginine (NMA), an inhibitor of NO production, did not 
influence the course of VACV infection (201) suggesting that while NO 
production controls viral replication, other factors could be sufficient for a 
complete clearance of the virus (200).  
 Induction of iNOS by IFN-γ leads to NO production in a different array of 
cells such as resident macrophages, fibroblasts, epithelial cells, keratinocytes, 
hepatocytes, mesangial cells and tumor cells (112, 113). Moreover, although IFN-
γ is not consider a traditional activator of neutrophils, it enhances the production 
of reactive oxygen species (ROS) in the presence of a secondary stimulus (57) 
and expression iNOS as well as NO production has been observed in neutrophils 
following induction with IFN-γ in a concentration dependent manner (245). This 
induction has also been observed in mouse RAW 264.7 macrophage-like cells 
where viral replication of VACV can be inhibited by the production of NO (113). 
Similarly, infection of sublethally irradiated CBA/H athymic nude mice with a 
recombinant VACV expressing iNOS under the control of the early-late P7.5 
promoter indicated that this virus is highly attenuated even following intracerebral 
infection (200). Attenuation was also observed when using a recombinant VACV 
virus expressing iNOS under the control of Escherichia coli LacI (152).  
 In a post-exposure prophylaxis context, production of NO by iNOS 
following treatment with v50ΔB13RMγ could increase the levels of nitrite after 
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infection, which is known to correlate with inhibition of VACV DNA replication 
and late gene protein synthesis, while no effect has been observed in the 
expression of early genes (99, 152).  
 In order to further examine the mechanism of action of v50ΔB13RMγ in 
the treated groups, the population of immune cells in each of the treated and 
untreated groups was evaluated using FACS analysis. Results showed an increase 
in the CD8+ T cell population in the treated group by 2 dpi in comparison to the 
untreated group and controls. Although it has previously been suggested that 
CD8+ T cells are not essential for wt VACV (WR) clearance (97, 244), these cells 
seems to be playing a role in preventing morbidity and reducing mortality 
although the mechanisms are not clearly understood. Thus, CD8+ T cells role in 
post-exposure prophylaxis could be similar as it has previously been observed in 
other studies although CD8+ T cells specificity for VACV needs to be determined. 
 While examining the population of immune cells that were recruited at the 
site of infection, it was noticed the reduction in numbers of a Gr1+B220+ cell 
population in the groups that were infected with wt VACV (Fig. 23). While such a 
specific population has not previously been described, Cd11c+B220+Gr1+ cells in 
mice are known as plasmacytoid dendritic cells, which are able to produce IFN-α 
as a response mechanism to viral infection (10). Future studies are required in 
order to determined if this Gr1+B220+ cell population is indeed composed of 
plasmacytoid dendritic cells and why their numbers are reduced upon infection 
with wt VACV. 
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 The presence of a higher population of Gr1+Cd11b+ cells, also known as 
myeloid derived suppressor cells or MDSCs, in animals treated with 
v50ΔB13RMγ at 1 dpi suggest that these cells may be playing an important role 
during post-exposure prophylaxis (Fig. 25). Gr1+Cd11b+ cells are a heterogeneous 
population of cells that include myeloid progenitor cells and immature myeloid 
cells and are thought to regulate the immune system in both healthy and sick 
individuals (75, 230, 251). Expansion of Gr1+Cd11b+ has been observed during 
acute and chronic infections with different organisms including Trypanosoma 
cruzi which is accompanied by an increased production of IFN-γ (82). Studies 
using a recombinant VACV expressing IL-2, which is thought to enhance the lytic 
capabilities of the CD8+ T cells, showed the apoptotic death of this population 
following immunization through a mechanism due to Gr1+Cd11b+ (22).  
 A possible role of Gr1+Cd11b+ during post-exposure prophylaxis could be 
the down-modulation of the immune response by for example inducing apoptosis 
of activated lymphocytes, which could potentially lead to tissue destruction. This 
hypothesis is supported by recent studies by Fischer et al. (69), in which depletion 
of cells positive for Ly6G, one of the two antigens that can be bound by Gr1, 
leads to more damaged tissue at the site of infection. It was also observed in the 
same study that the Cd11b+Ly6C+Ly6G+ population produces type I IFN and  
protects the VACV-infected tissue from immune-mediated damage by producing 
ROS molecules (69).  
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 In order to better understand how v50ΔB13RMγ may be modulating the 
TH1 and TH2 cytokine levels, the cytokines from each group were analyzed using 
a Bio-plex assay. Upon examination of the results, the cytokine/chemokine 
profiles were similar among wt VACV-infected and wt VACV-infected/ 
v50ΔB13RMγ treated groups suggesting that immunoregulatory effects were 
local. While differences among the untreated and treated groups were not 
observed, it was noted that levels of IL-12 at 2 dpi were higher in the treated 
group compared to the mock-infected, mock-treated group. IL-12 is a TH1 
cytokine secreted by activated dendritic cells and macrophages and is the 
principal mediator of the early innate immune response to intracellular microbes 
(2, 52, 184). In the case of TH2 cytokines, IL-5 levels were higher in the treated 
group at 2 dpi while IL-10 levels were higher in both the untreated and treated 
group when compared to the mock-infected/mock-treated group and the mock-
infected/v50ΔB13RMγ-treated group. While IL-5 is produced by activated mast 
cells and stimulates the growth and differentiation of eosinophils as well as the 
activation of the mature eosinophils, IL-10 is produced by activated macrophages 
and its major role is to maintain homeostasis between the innate and cell-mediated 
immune response by inhibiting activated macrophages (2). Further studies are 
necessary in order to determine the specific role of these cytokines during post-
exposure prophylaxis of VACV in this animal model.  
 Analysis of the specific chemoattractants, MIP-1β, MIP-2 and RANTES 
show higher levels of these proteins at in both untreated and treated groups by 6 
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dpi. MIP-1β is a chemokine produced by macrophages, dendritic cells and 
lymphocytes and it is involved in the recruitment and activation of granulocytes 
(211). MIP-2, on the other hand, is produced by epithelial cells and peripheral 
neutrophils and its function is to attract neutrophils to the sites of inflammation 
following injury and/or infection (8). RANTES expression has been observed in 
delayed-type hypersensitivity reactions and has been shown to be mediated by 
TNF-α and IFN-γ. This chemokine is released by cytotoxic T lymphocytes 
(CTLs) and is a selective attractant for T cells and monocytes (211). Furthermore, 
activation of CTLs through RANTES is mediated through cell surface 
aggregation, which could be prevented by MIP-1β (7).  
 Overall, the results presented in this chapter indicate that v50ΔB13RMγ is 
modulating the immune response by mostly promoting the Gr1+Cd11b+ as well as 
the CD8+ T cell populations at early time post-infection. It was also observed that 
treatment with v50ΔB13RMγ has an effect in wt VACV replication in the 
olfactory bulb. This is of particular importance as the olfactory bulb in the animal 
model currently studied appears to be one of the entry points of VACV to the 
central nervous system.  A delay in viral replication in this part of the brain would 
therefore play a key role in the morbidity and ultimately mortality in this post-
exposure prophylaxis model. 
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FIG. 15. Role of IFN-γ in the immune response. IFN-γ promotes the 
differentiation of naïve CD4+ T cells (TH0) to the TH1 subset, which in turn 
secrete IFN-γ. Among the biological functions of IFN-γ are macrophage 
activation, reinforcement of cytotoxic T lymphocytes (CTL) activity, 
enhancement of natural killer (NK) cell activity, neutrophil activation and isotype 
switching (IgG2a in mice), which promotes opsonization and phagocytosis.  
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FIG. 16. Neutrophil spread in the maxilloturbinate section of wt VACV infected 
mice. Mice were infected intranasally with 106 pfu (~100 LD50s) of wt VACV and 
treated 1 dpi with 107 pfu of v50ΔB13RMγ. (A) Samples at 3dpi and (B) samples 
at 8 dpi. All representative sections were obtained at 2 mm depth and were stained 
with polyclonal antibodies against VACV and 7/4 'anti neutrophil'. S= septum, 
T=maxilloturbinate, M=meatus (air passage). 100X magnification.  
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FIG. 17. Olfactory bulb section and its main components. A group of C57/BL6 
mice were mock-infected and mock-treated intranasally at 1 dpi. The histology 
section depicts the olfactory bulb of one of these mice from this control group. 
100X magnification.  
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FIG. 18. VACV replication in the olfactory bulb section. Mice were infected 
intranasally with 106 pfu (~100 LD50s) of wt VACV and treated 1 dpi with 107 pfu 
of v50ΔB13RMγ. Mice were sacrificed at 8 days post-infection. Representative 
sections were obtained at 4 mm depth and were stained with polyclonal antibodies 
against VACV. OB= olfactory bulb, S=septum, NPM=nasopharyngeal meatus, 
HP=hard palate. (A) wt VACV infected / Mock treated (B) wt VACV infected / 
v50ΔB13RMγ treated. 10X magnification.  
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FIG. 19. Histopathologic comparison and infection progression in the olfactory 
bulb section. Mice were infected intranasally with 106 pfu (~100 LD50s) of wt 
VACV and treated 1 dpi with 107 pfu of v50ΔB13RMγ. All representative 
sections were obtained at 4 mm depth and were stained with polyclonal antibodies 
against VACV and 7/4 'anti neutrophil'. OB= olfactory bulb, CP=cribriform plate. 
(A) 100X magnification. (B) 400X magnification. 
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FIG. 20. Viral spread of wt VACV in the olfactory bulb and brain of infected 
animals. Groups of 5 C57BL/6 mice were mock-infected or infected intranasally 
with 106 pfu of wt VACV. Animals remained untreated or were treated one day 
post-infection with 107 pfu of v50ΔB13R or v50ΔB13RMγ. Samples were 
collected and analyzed at 2 and 6 dpi. (A) Replication in the olfactory bulb. (B) 
Replication in the brain. Error bars indicate the standard error of the mean.     
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FIG. 21. Susceptibility of NOS2-/- mice after intranasal infection with different 
doses of wt VACV and subsequent treatment with v50ΔB13RMγ. Groups of 5 
four-week-old NOS2-/- mice were infected intranasally with 102 pfu (<1 LD50s), 
104 pfu (1 LD50) or 106 pfu (100 LD50s) of wt VACV and treated one day post-
infection with 107 pfu of v50ΔB13RMγ. A group of 5 four-week-old C57BL/6  
mice served as control animals and included mock-treated (■), mock-infected and 
mock-treated (◊) and animals treated with v50ΔB13RMγ (▲).  
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FIG. 22. Treatment of infected animals with v50ΔB13RMγ enhances proliferation 
of CD8+ T cells. Groups of five C57BL/6 mice were either mock-infected or 
infected intranasally with 106 pfu (~100 LD50s) wt VACV. Animals were treated 
with 107 pfu of v50ΔB13R, v50ΔB13RMγ or mock-treated at 1 dpi. On days 2 
(A) and 6 (B) post-infection, nasal lavages were collected and analyzed for CD3+ 
by flow cytometry. Data are representative of two independent experiments.   
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FIG. 23.  Infection of animals with wt VACV reduces the Gr1+ B220+ cell 
population at the site of infection. Groups of five C57BL/6 mice were either mock 
infected or infected intranasally with 106 pfu (~100 LD50s) wt VACV. Animals 
were treated with 107 pfu of v50ΔB13R, v50ΔB13RMγ or mock treated at 1 dpi. 
On days 2 and 6 post-infection, nasal lavages were collected, pooled and analyzed 
for Gr1 and B220 by flow cytometry. Data are representative of two independent 
experiments.   
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FIG. 24. Infection of animals with wt VACV does not affect the population of 
CD49+ (NK) cells at the site of infection. Groups of five C57BL/6 mice were 
either mock infected or infected intranasally with 106 pfu (~100 LD50s) wt VACV. 
Animals were treated with 107 pfu of v50ΔB13RMγ or mock treated at 1 dpi. On 
days 2 and 6 post-infection, nasal lavages were collected, pooled and analyzed for 
CD49 and CD11b by flow cytometry. Data are representative of two independent 
experiments.   
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FIG. 25. Treatment of infected animals with v50ΔB13RMγ enhances proliferation 
of Gr1+ CD11b+ myeloid-derived suppressor cells by day 2 post-infection.  
Groups of five C57BL/6 mice were either mock infected or infected intranasally 
with 106 pfu (~100 LD50s) wt VACV. Animals were treated with 107 pfu of 
v50ΔB13R, v50ΔB13RMγ or mock treated at 1 dpi. On days 2 and 6 post-
infection, nasal lavages were collected, pooled and analyzed for Gr1 and CD11 by 
flow cytometry. Data are representative of two independent experiments.   
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FIG. 26. Polarized TH1 and TH2 responses. Both TH1 and TH2 subsets produce 
distinct set of cytokines and have distinct effector functions. While TH1 cells 
promote cell-mediated immunity and phagocyte-dependent inflammation, TH2 
cells enhance strong antibody responses and eosinophil accumulation (phagocyte-
independent inflammation). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Naïve CD4+ (TH0) 
TH1 cell TH2 cell 
B cell Macrophage 
IFN-! 
IL-4 
IL-4 
IL-5 
IL-12 
IFN-! 
TNF-" 
IL-10 IL-2 
 81 
 
 
 
 
 A                     B 
 
 
          C 
 
 
 
    
   
 
 
 
 
 
 
 
 
 
 
 
FIG. 27. Expression of Th1 cytokines in infected animals. Groups of five 
C57BL/6 mice were either mock infected or infected IN with 106 pfu (~100 
LD50s) wt VACV. Animals were treated with 107 pfu of v50ΔB13RMγ or mock 
treated at 1 dpi. Nasal lavages were collected and analyzed using the Bio-plex 
system. IL-12 (A), TNF-α (B) and IFN-γ (C). * P<0.05, ** P<0.01, *** 
P<0.0001. 
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FIG. 28. Expression of Th2 cytokines in infected animals. Groups of five 
C57BL/6 mice were either mock infected or infected IN with 106 pfu (~100 
LD50s) wt VACV. Animals were treated with 107 pfu of v50ΔB13RMγ or mock 
treated at 1 dpi. Nasal lavages were collected and analyzed using the Bio-plex 
system. IL-5 (A), IL-10 (B) and GM-CSF (C). * P<0.05, ** P<0.01, *** 
P<0.0001. 
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FIG. 29.  Expression of chemoattractans and IL-6. Groups of five C57BL/6 mice 
were either mock infected or infected IN with 106 pfu (~100 LD50s) wt VACV. 
Animals were treated with 107 pfu of v50ΔB13RMγ or mock treated at 1 dpi. 
Nasal lavages were collected and analyzed using the Bio-plex system. MIP-1β 
(A), MIP-2 (B), RANTES (C) and IL-6 (D). * P<0.05, ** P<0.01, *** P<0.0001. 
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CHAPTER 3 
DUAL EXPRESSION OF THE VACCINIA VIRUS E3L PROTEIN Z-DNA 
AND DOUBLE-STRANDED RNA BINDING DOMAINS 
  
ABSTRACT 
 Vaccinia virus (VACV) is a member of the genus Orthopoxvirus of the  
family Poxviridae and it is considered a highly effective vaccine against smallpox  
and other closely related viruses such as monkeypox and cowpox. VACV has a  
double stranded DNA genome approximately 190 Kbp in length and encodes for  
about 200 proteins. One of the main characteristics of this virus is that it is  
interferon (IFN) resistant as evidenced by replication of VACV in cultured cell  
lines treated with type I IFN. This effect is primarily mediated by the protein  
encoded by the E3L gene as deletion of the entire gene renders a VACV that is  
IFN sensitive.  The E3L protein has two main domains: a Z-DNA binding domain  
contained in the amino terminus, and a double-stranded RNA binding domain in  
the carboxy terminus. Both domains have been shown to be necessary for  
pathogenesis as a VACV mutant lacking the Z-DNA binding domain is less  
pathogenic than wild type in intranasal infections. A virus that expresses both  
domains of E3L was constructed and compared to wild type VACV in cells in  
culture and for its ability to inactivate the IFN response. The dual expression virus  
was unable to replicate in JC cells, a cell line where E3L mutants lacking either  
the Z-DNA binding domain or the dsRNA binding domain are unable to replicate.  
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Moreover, phosphorylation of the dsRNA dependent protein kinase (PKR) was  
observed at late times post-infection. The present data support the hypothesis that  
both domains of E3L need to be linked together in order to block the IFN  
response suggesting that the Z-DNA binding domain of E3L could bind to dsRNA  
in its Z-form.  
  
INTRODUCTION 
 Vaccinia virus (VACV) is a member of the genus Orthopoxvirus of the   
Poxviridae family. Other members from this family include variola virus  
(VARV), the causing agent of smallpox; monkeypox virus (MPXV), ectromelia  
virus (ECTV) and cowpox virus (CPXV) (66, 160). After an intensive vaccination  
strategy initiated in 1967, smallpox was declared eradicated from the world in  
1980 and routine smallpox vaccination was discontinued in the U.S. in 1972  
(237). Following September 11, 2001, the potential use of VARV as a  
bioterrorism agent is of particular concern, as it constitutes an ideal terrorist  
weapon of mass destruction (135). Moreover, there also remains a low but very  
real risk of VARV release, whether intentional or accidental (227).   
 Responsible for the eradication of the smallpox and able to induce  
antibodies that protect against monkeypox virus (56), VACV is also used as an  
expression vector for foreign genes and as a live recombinant vaccine for  
infectious diseases and cancer (144, 151). Unfortunately, inoculation in humans  
with VACV can lead to severe complications, especially in children and  
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immunocompromised individuals thus, a safer vaccine as well as a better  
understanding of the vaccine vector has become necessary (58).    
  One of the main characteristics of VACV is that it is interferon (IFN)  
resistant and the mechanisms by which this virus evades the host response (Fig.  
30) are currently being investigated. In VACV, E3L is the major IFN resistance  
gene (106), which has also been associated with neurovirulence in mice (19, 122).  
E3L codes for two proteins, p25 (190 amino acids) and a smaller protein p20 (153  
amino acids), which is generated due to leaky scanning during translation (36).  
E3L has two main defined domains, a C-terminal dsRNA binding domain  
(dsRNA BD) that is required for both replication in many cells in culture and  
pathogenesis in mice, and an N- terminal Z-DNA binding domain (Z-DNA BD)  
that is dispensable for replication in cells in culture, but required for pathogenesis  
(122) (Fig. 31). Moreover, the C-terminus has been associated with IFN resistance  
and PKR inhibition, although recent data show that the N-terminus is also  
necessary for both IFN resistance and PKR inhibition (235). These new data  
provide new insight into the function of the N-terminus in vivo. This N-terminus  
domain is highly conserved in poxviruses and in VACV has been proven to be  
necessary for neurovirulence in mice and its spread from the nose to the brain  
(neuroinvasion) in VACV infection in C57/BL6 mice (18, 122). Furthermore, the  
N-terminus is necessary to inhibit PKR activation at late times post-infection and  
eIF2α phosphorylation in HeLa cells as well as in nasal turbinates of C57/BL6  
mice (132).    
 87 
  The N-terminus of E3L is a member of the Zα family of Z-DNA binding  
domains. Other members in this family include the human adenosine deaminase  
acting on RNA 1 (ADAR1), mouse Z-DNA binding protein 1 (ZBP1) and fish  
PKR like kinase, PKZ (122, 205) (Fig. 32). Each of these Zα domains, including  
the one from E3L, is characterized by a helix-turn-helix motif with an additional  
β-sheet (Fig. 33A). Although the structures are very similar, the amino acid  
sequence is not conserved, except for the residues that contact DNA (122). This  
was proven to be true when the Zα domain of E3L was substituted for other Zα  
domains. Indeed, both chimeric viruses ZαADAR1-E3Lc and ZαDLM1-E3Lc retain the  
same pathogenicity as wt VACV after intracranial (IC) infection (122).   
Interestingly, the solution structures of the Zα domain of E3L, ZαADAR1 and  
ZαDLM1 are very similar but differ in the side chain conformation of a key Z-DNA  
contacting residue Y48 (110, 122). This difference could explain why the Zα  
domain has a reduced affinity to Z-DNA in vitro, although in vivo other factors  
could render wt E3L as pathogenic as the ZαADAR1-E3Lc chimera (110, 122). The  
Zα domain of E3L has also proven to be important in the transcriptional activation  
of human IL-6, NF-AT and p53 as well as in the inhibition of hygromycin B-  
induced apoptosis in HeLa cells (129).    
 Both B-DNA and A-RNA helices can undergo a transition to left-handed  
double helical structures forming Z-DNA and Z-RNA respectively. In the case of  
Z-DNA, negative supercoiling and high-salt conditions have been previously  
shown to stabilize the structure (194). Nevertheless the transition of A-RNA to Z- 
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RNA seems to require higher salt concentrations and higher temperatures,  
although Z-RNA can also be formed at lower temperatures during longer  
transitions (92). In a more physiological-like environment a B to Z-DNA  
transition can be induced in alternating purine - pyrimidine sequences by adding  
the Zα domain from ADAR1 while mutations in the key residues that contact the  
DNA reduce the ability of the protein to convert B-DNA to Z-DNA as  
demonstrated by circular dichroism (122). Similarly, this domain has been proven  
to stabilize the Z-RNA conformation making both Z-DNA and Z-RNA targets of  
ADAR1 (23), which has been corroborated by the recent crystal structure of the  
ZαADAR1/Z-RNA complex. The complex revealed that the same key residues are  
involved in binding both Z-DNA and Z-RNA (179) giving an insight into the new  
possible biological function of the Zα domain of E3L.    
 Transition of A-RNA to Z-RNA has been previously described at high salt  
concentrations (6M NaClO4) and high temperatures (45°C) (92). The nuclear  
magnetic resonance (NMR) structure of Z-RNA has been obtained at this high salt  
concentration although at a lower temperature (30°C) (181). More recently, the  
crystal structure of ZαADAR1 bound to Z-RNA has been obtained at a lower salt  
concentration (0.1 M Na+ versus 6 M Na+) (179). Moreover, although both  
structures depict Z-RNA, differences in the structures point to a ZR (novel left-  
handed helix) and ZD (Z-DNA-like conformation). These two distinct forms of Z-  
RNA have been previously observed using Raman spectroscopy at different  
at 35°C for ZR-RNA (96). It is believed that ionic strength is the driving force  
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behind both conformations and that the A-to ZD transition is followed by a ZD to  
ZR transition.  It has also been noted that chemical bromination of poly[r(C-G)]  
has a profound effect on the conformation properties of the RNA duplex. A  
limited chemical bromination of poly[r(CG)] (32% br8G, 26% br5C) produces a  
1:1 ratio mixture of A and Z-forms of RNA while a more extensive bromination  
of poly[r(CG)] (>49% br8G, 43% br5C) results in stabilization of the ZD form  
(96, 153).   
 The C-terminus of E3L contains a dsRNA binding domain. Previous  
deletion analyses localized the domain necessary for binding dsRNA between  
amino acids 83 and 183 (34), although this domain is limited to amino acids 117  
to 182 (102, 103) (Fig. 33B). Other proteins containing this dsRNA binding 
domain include PKR, ADAR1, Drosophila melanogaster staufen, and 
Escherichia coli RNase III (102). The presence of this domain in E3L is 
important, as dsRNA produced during viral infections is the alerting mechanism 
to initiate the type I IFN pathway (36). VACV evades this mechanism by binding 
to dsRNA via E3L and inhibiting the interferon induced effector molecules 2’-5-
oligoadenylate synthetase and PKR. By doing this E3L prevents inhibition of both 
viral and host proteins synthesis as well as apoptosis (119). Participation of Zα 
domain of E3L in the inhibition of PKR activation by also masking dsRNA would 
constitute a novel biological function for this domain; thus, binding to dsRNA 
would not be limited to the C-terminal dsRNA binding domain of E3L.  
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MATERIAL AND METHODS 
 Cells and viruses. Baby hamster kidney (BHK-21) cells and Rabbit  
kidney cells (RK-13) were cultured in Eagle's Minimal Essential Medium (MEM,  
Gibco, BRL) containing 5% fetal bovine serum (FBS, Hyclone) and 50 µg/ml of  
gentamycin. Epithelial cells from the kidney of Cercopithecus aethiops also  
known as African green monkey kidney cells (BSC-40) were grown in Dulbecco's  
modified Eagle's medium (DMEM, Gibco, BRL) supplemented with 10% FBS  
(Hyclone) and 50 µg/ml of gentamycin. JC cells (ATCC CRL-2116) were grown  
in RPMI-1640 Medium containing 10% FBS. All cells were incubated at 37°C  
with 5% CO2. The Western Reserve (WR) strain of VACV was used as the  
parental virus for these studies. The E3L VACV mutants were generated by  
standard methods routinely employed in Dr. Bertram Jacobs' laboratory.  
Construction of VACV mutants have previously been described (119).  
VACVΔE3LΔTK::GP-GNR has Gyrase PKR and the green fluorescent protein  
(GFP) fused to a neomycin resistant gene driven by a double synthetic promoter  
in the TK locus, lacZ is in place of E3L (James Jancovich, unpublished). All  
viruses were amplified in BHK-21 cells and partially purified by pelleting through  
a 36% sucrose pad, as previously described (15, 54).   
 Plasmids construction. Standard PCR techniques were employed in the  
construction of the plasmids with Platinum® Pfx DNA Polymerase (Invitrogen).  
In order to generate a plasmid where the entire sequence for the dsRNA binding  
domain was deleted, the E3L sequence for nucleotides 1 to 351 was amplified  
 91 
from the plasmid pMKE3L (Jacobs' laboratory) using the primers Δ73C-FLAGF   
and Δ73C-FLAGR (Table 1), and cloned into the BamHI and PstI restriction sites  
of the plasmid pJC1 producing the recombinant plasmid pJC1-Δ73C-FLAG. The  
parental pJC1 was previously constructed (Jason Cameron, unpublished) by  
altering pMPE3ΔGPT, a vector previously described (119). The plasmid pJC1  
contains both the native promoter of E3L (preceding BamHI and HindIII sites)  
and a synthetic early-optimized promoter (EOP) 5'  
AAAAATTGAAAAACTATTCTAATTTATTGCACGG 3' preceding the SalI  
and PstI restriction sites. The plasmid pJ1R-J3R was constructed in a two-step  
process using pUC19 as a backbone. Briefly, primers to generate a 478 bp J1R  
arm were designed using the VACV sequence for the WR strain (GenBank  
accession number AY243312). The primer J1RF containing an NdeI site and J1RR  
containing a SacI site (Table 1) were used to amplify the J1R fragment using  
cDNA from wt VACV as a template. The J1R fragment was then cloned into  
pUC19 NdeI and SacI sites resulting in plasmid pJ1R. A 488 bp J3R arm was then  
generated similarly using primers J3F with a XmaI site and J3RR with a PstI site  
(Table 1). The resulting fragment was cloned into the XmaI and PstI sites of pJ1R  
resulting in the recombinant plasmid pJ1R-J3R. A PCR product containing a  
deletion of the sequence coding for the N-terminus was then made by amplifying  
E3L nucleotides 250 to 573 from pJC1-AEIK using primers Δ83N-FLAGF with a  
SacI site and Δ83N-FLAGR with a XmaI site (Table 1), resulting in a fragment  
with the EOP at the 5' end. pJC1-AEIK was previously constructed by cloning  
 92 
E3L nucleotides 1 to 249 with a sequence coding for an N-terminus HIS-tag in the  
BamHI and HindIII sites and E3L nucleotides 250 to 573 with a sequence coding  
for an N-terminus FLAG sequence into the SalI and PstI restriction sites of pJC1.  
Another similar PCR product was made with using primers Δ83N-FLAGoppF  
with a SacI site and Δ83N-FLAGoppR with a XmaI site (Table 1), the 3' end of  
this PCR product contains the EOp sequence reading at the opposite direction.  
The products were cloned into the SacI and XmaI sites of pJ1-J3 resulting in  
pJ1R-FLAG-Δ83N-J3R and pJ1R-FLAG-Δ83Nopp-J3R. All the generated PCR  
products were purified using the Wizard® SV Gel and PCR Clean-Up system  
(Promega) according to manufacturer's protocol. Vectors were dephosphorylated  
with the enzyme Antarctic Phosphatase (New England Biolabs) and ligated to the  
PCR products using T4 DNA ligase (New England Biolabs). Ligation reactions  
were precipitated with glycogen overnight and transformed into Subcloning  
EfficiencyTM DH5αTM chemically competent E. coli (Invitrogen). Following a  
standard alkaline lysis protocol, recombinant plasmids were verified by DNA  
sequencing.  
 Plasmid In vivo recombinations. Recombinant viruses were generated by  
plasmid in vivo recombination (PIVR). Plasmid pJC1-Δ73C-FLAG, which has a  
pMPE3Δgpt backbone, allows insertion of genes into the E3L locus of  
VACVΔE3LΔTK::GP-GNR by homologous recombination. Recombinant  
VACVE3LΔ73CF was selected due to their resistance to mycophenolic acid  
(MPA), an inhibitor of purine metabolism. Only recombinant viruses that inserted  
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the ecogpt gene in their genome are able to overcome the inhibition of purine  
metabolism by MPA (61) (107). After three rounds of plaque purification in RK-  
13 cells, the selection was removed allowing a second recombination event to  
occur. The insertion of the gene of interest into VACV was screened for by loss of  
lacZ; thus, colorless plaques were picked instead of blue plaques (107). The  
resulting virus, VACVE3LΔ73CF, has GFP in the TK locus thus plaques fluoresce  
green. Plasmids pJ1R-FLAG-Δ83N-J3R and pJ1R-FLAG-Δ83Nopp-J3R allow  
insertion into the J2R (TK) locus by homologous recombination. PIVR reactions  
were done using VACVΔE3L virus (for controls) and VACVE3LΔ73CF. Three  
rounds of selection were done in BSC-40 cells and white plaques instead of green  
were picked in each round. The resulting recombinant viruses were  
VACVE3LΔ73CF-TK::FE3LΔ83N and VACVE3LΔ73CF-TK::FE3LΔ83Nopp.  
All recombinant viruses were amplified in BHK-21 cells. An aliquot of the  
amplified virus was used for phenol/chloroform genomic DNA extraction and  
DNA sequencing.   
 Detection of the E3L domains by Western blot. Subconfluent cell  
monolayers in 60 mm dishes were infected at a multiplicity of infection (MOI)  of  
5 and processed at the indicated times. Samples were harvested by scraping the  
cells into 1X SDS sample buffer containing β-mercapto-ethanol and passing them  
through a QIAshredder homogenizer (QIAGEN) followed by a centrifugation step  
of two minutes at 16,000 g. Samples were heated at 95°C for five minutes and  
protein resolved on a 20% SDS-PAGE gel. Proteins were then transferred  
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overnight at 4°C to a Polyvinylidene fluoride (PVDF) membrane. The membrane  
was blocked with 1X TBS with Tween-20 containing 3% instant non-fat dry milk  
and probed with Anti-FLAG (clone M2) antibodies (Sigma) made in mouse or  
E3L antibodies (Jacobs' laboratory) made in rabbit. Proteins were detected by  
chemiluminescense (Pierce) and exposure to X-ray films.   
 Activated PKR and eIF2α phosphorylation assays. Subconfluent HeLa  
cells were infected at an MOI of 5. At 4 and 9 hours post-infection cell lysates  
were prepared as described in the previous section. Protein samples were resolved  
on a 10% SDS-PAGE gel. Separated proteins were then transferred for one hour  
at 100V to a nitrocellulose membrane, blocked with 1X TBS with Tween-20  
containing 3% instant non-fat dry milk and probed with rabbit anti-eIF2α phospho  
(Ser 51) antibodies from Cell Signaling or rabbit anti-PKR phospho (Thr 446)  
antibodies from Epitomics. Proteins were detected by chemiluminescense (Pierce)  
and exposure to X-ray films. Following detection membranes were stripped using  
stripping buffer (62.5 mM Tris-HCl ph 6.8, 2% SDS, 100 mM beta  
mercaptoethanol) and probed with rabbit anti-PKR antibodies (Epitomics) or anti-  
eIF2α antibodies (Epitomics). Detection was done by chemiluminescense (Pierce)  
as described above. Membranes were then stripped and re-probed using rabbit  
anti-GAPDH antibodies (Abcam) in order to ensure that equal amounts of  
proteins were loaded.   
 Host range. Six well plates of BSC-40 and RK13 E3L cells were infected  
with several dilutions of virus in 1 mM Tris HCl pH 8.8. Plates were rocked every  
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10 minutes in order to keep the monolayers moist. After one hour the cells were  
overlaid with their appropriate media (DMEM 10%FBS for BSC-40 cells and  
MEM 5% FBS for RK13 cells). When plaques were visible (~30 hours), the  
monolayers were stained with crystal violet (0.5% in 20% ethanol). Plaques were  
counted and the titer was calculated for each virus. The efficiency of plaquing  
(EOP) was calculated by dividing the pfu/ml in BSC-40 cells by the pfu/ml in  
RK13 cells.  
 Multi-step growth curve. Four replicas of confluent JC cells seeded in 35  
mm dishes were infected with the viruses described in Fig. 28 and the respective  
controls. The cells were rocked every 10 minutes for one hour. At one hour post-  
infection the inoculum was removed and the cells were washed three times with  
warm phosphate buffered saline (PBS). The cells were then overlaid with RPMI  
media containing 10% FBS. One set (two replicas) of the infected dishes was then  
harvested by scraping the cells into the media. Cells were then centrifuged at  
2,000 g for 10 minutes at 4°C. The supernatant was discarded and the pellet  
resuspended in 1 mM Tris HCl pH 8.8, the samples were then subjected to three  
rounds of freeze/thaw (one hour at -80°C, 30 minutes on ice, two minutes at  
37°C). Samples were then centrifuged and the supernatant was transferred to  
another tube. This first set of samples was considered the 0 hours post-infection  
time point. Another set of samples (two replicas) was harvested at 72 hours post-  
infection in a similar manner. Both set of samples were used to infect RK13 E3L   
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cells and the titers from the input virus (0 hours) with the titers were the virus  
went through multiple cycles of replication (72 hours) were compared.   
  
RESULTS 
 Generation of recombinant viruses. In order to study the dual expression  
of both the Zα domain and the dsRNA binding domain of E3L, VACVE3LΔ73CF-  
TK::FE3LΔ83N and VACVE3LΔ73CF-TK::FE3LΔ83Nopp were constructed in  
the WR background by PIVR using the plasmid vectors pJ1-FLAGΔ83N-J3 and  
pJ1-FLAGΔ83Nopp-J3 as described in the material and methods section. In these  
viruses the native E3L promoter drives the region that codes for the Zα domain in  
the E3L locus while an early optimized promoter, EOP, drives the region that  
codes for the dsRNA binding domain in the TK locus (Fig. 34). The sequence of  
EOP was previously obtained by combining several mutations that resulted in  
having a greater effect on expression of β-galactosidase in vitro (44).    
 Confirmation of the dual expression of Zα domain (N-terminus) and  
the dsRNA binding domain (C-terminus) of VACV E3L. Preliminary results  
from Western blots have shown that viruses with the EOP have the same relative  
amount of protein at early and late times post-infection indicating that both the  
native E3L promoter and EOP function similarly (data not shown). The FLAG tag  
was added to the C-terminus of the Zα domain so this domain will retain the wild  
type Kozak sequence next to the first codon of the E3L protein. Similarly, the  
dsRNA binding domain has the FLAG tag in the N-terminus. In order to check for  
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functional protein expression, BHK cells were infected with the recombinant  
VACV viruses and controls made using the constructs depicted in Fig. 34. The  
infected cells were harvested at 6 hours post-infection and proteins resolved on a  
20% SDS-PAGE gel. Proteins were then transferred overnight at 4°C to a PVDF  
membrane. Protein levels were compared among the different viruses by probing  
with antibodies specific for the FLAG tag. Equal expression of both domains can  
be observed for VACVE3LΔ73CF-TK::FE3LΔ83N (Fig. 35, lane 8) and  
VACVE3LΔ73CF-TK::FE3LΔ83Nopp (Fig. 35 lane 9). E3L antibodies were also  
used in order to detect both the Zα domain and the dsRNA binding domain of  
E3L (Fig. 36).  
 PKR activation and eiF2α phosphorylation. It has been previously  
demonstrated that the dsRNA binding domain of E3L is required to inhibit the  
activation of PKR (132). In order to determine the activation of PKR and the  
subsequent phosphorylation of eIF2α, HeLa cells were infected and cells were  
harvested at 4 and 9 hours post-infection. Proteins were then resolved in a 10%  
SDS-PAGE gel, transferred into a nitrocellulose membrane and probed with  
antibodies specific for the phosphorylated forms of PKR and eIF2α. Infection of  
HeLa cells with VACVΔE3L, VACVE3LΔ73C and VACVE3LΔ73CF (Fig. 37,  
lanes 2, 4 and 5 respectively) resulted in phosphorylation of PKR at 4 hours post-  
infection. PKR phosphorylation levels were higher in VACVΔE3L,  
VACVE3LΔ73C and VACVE3LΔ73CF (Fig. 37, lanes 2, 4 and 5 respectively) as  
well as in VACVE3LΔ73CF-TK::FE3LΔ83N (Fig. 37, lane 8) and  
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VACVE3LΔ73CF-TK::FE3LΔ83Nopp (Fig. 37, lane 9) by 9 hours post-infection,  
although less phosphorylation of PKR was observed in the VACVE3LΔ73CF-  
TK::FE3LΔ83N virus compared to VACVE3LΔ73CF-TK::FE3LΔ83Nopp. When  
PKR is phosphorylated it leads to the phosphorylation of eIF2α (Fig. 30). To  
determine if phosphorylation of PKR correlated with eIF2α phosphorylation, the  
protein-bound membranes were probed with antibodies specific for the  
phosphorylated form of eIF2α. Infection of HeLa cells with VACVΔE3L,  
VACVE3LΔ73C and VACVE3LΔ73CF (Fig. 38, lanes 2, 4 and 5 respectively)  
resulted in phosphorylation of eIF2α by 4 hours post-infection while eIF2α  
phosphorylation was observed in VACVΔE3L, VACVE3LΔ73C and  
VACVE3LΔ73CF (Fig. 38, lanes 2, 4 and 5  respectively) as well as in  
VACVE3LΔ73CF-TK::FE3LΔ83N (Fig. 38, lane 8) and VACVE3LΔ73CF-  
TK::FE3LΔ83Nopp (Fig. 38 lane 9) by 9 hours post-infection.  
 Host range phenotype of VACV E3L mutants. Wild type VACV has  
previously been shown to have a broad host range (213). Moreover, it has been  
demonstrated that E3L has a role in the host range by regulating PKR activity.  
VACVΔE3L is unable to grow in HeLa cells because the endogenous level of  
PKR is higher in the HeLa cells compared to BHK cells, which support the  
growth of the mutant VACV (133). Thus, the host range restriction of VACV is  
closely tied in with the anti-viral state of a cell and on the ability of the virus to  
disable the host response to infection. While VACV E3L C-terminal mutants are  
able to replicate in BHK and RK13 cells, they are not able to replicate in HeLa  
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cells (213) or BSC-40 cells (Jacobs' laboratory, unpublished data). On the other  
hand, VACV E3L N-terminal mutants are able to grow in BHK, RK13, HeLa and  
BSC-40 cells (broad host range) indicating that the amino terminus is dispensable  
for virus replication in these cell lines (14, 35, 241). Plaque assays in RK13 and  
BSC-40 cells using equal amounts of the recombinant viruses constructed were  
done in order to get data regarding the host range of these mutants. All viruses  
were able to replicate in RK13 cells while only the viruses that have the Zα  
domain of E3L intact were able to replicate in BSC-40 cells (Table 2).  
 E3L Zα domain needs to be linked to the dsRNA biding domain for  
replication in JC cells. Another cell line that was used in order to evaluate the  
mutants is the JC cell line. The JC cells are epithelial cells obtained from the  
mammary glands of mice with adenocarcinoma and have been useful in the  
characterization of amino terminal mutants (100, 228). JC cells were infected at  
an MOI of 0.05 and harvested at 0 hours and 72 hours post-infection in order to  
determine the input and resultant titer following several rounds of viral  
replication. As observed in Fig. 33 only wt VACV was able to replicate in this  
cell line indicating that both the Zα domain and the dsRNA binding domain of  
E3L need to be linked together in order for a virus to replicate. These findings  
correlate with previous results of a similar experiments that showed replication in  
the JC cells of the ZαADAR1-E3LC chimera where both domains are fused (data not  
shown).  
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DISCUSSION 
 This chapter provides insights into the role of the N-terminal Z-DNA  
binding domain of E3L, a protein that is primarily responsible for making VACV  
IFN resistant (133). Although VACV, the agent used in the smallpox vaccine, is  
one of the most effective vaccines ever used, it can cause severe complications  
after vaccination especially in immunosuppressed individuals (66). In the last four  
decades safer and highly immunogenic candidate VACV vaccines have been  
developed for a variety of uses (47, 108, 118). Some of these safer effective  
alternatives focus on the modulation of immune evasion genes (136, 137). As it  
was previously mentioned, one of these VACV immune evasion genes is E3L.  
E3L contains two domains with apparently non-overlapping functions. The C-  
terminus binds to dsRNA and inhibits the activation of the IFN-inducible proteins,  
protein kinase R (PKR) and 2’-5’ oligoadenylate synthase (OAS) (19). Binding to  
dsRNA also inhibits phosphorylation of a constitutively expressed transcription  
factor, IRF-3, which in turn leads to inhibition of IFN-β production (217). The N-  
terminus, on the other hand, contains a Z-DNA binding domain, which belongs to  
the Zα family (129). Deletion of this domain renders VACV apathogenic as  
demonstrated in previous studies indicating a role for Z-DNA binding in VACV  
pathogenesis and neurovirulence in infected mice (122).    
  The goal of this chapter was to elucidate the functions of the E3L domains  
in the evasion of the IFN response and to determine the possible interaction of  
both domains with dsRNA after viral infection. The specific hypothesis behind  
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this research is that the N-terminus of E3L inhibits PKR activation by interacting  
with dsRNA in its Z-form and that this interaction is mediated by binding of the  
C-terminus to the same molecule (Fig. 40). This hypothesis was based on the  
following observations:  First, deletion of type I IFN receptors (IFNα/βR -/-) in  
mice restores the pathogenicity of VACVE3LΔ83N to wild type levels (235).  
Second, in mouse embryo fibroblasts (MEFs) from the parental strain (129SV) of  
the IFNα/βR -/- mice, E3LΔ83N is IFN sensitive and this is mediated by  
phosphorylation of the PKR substrate, eIF2α (235). Third, this sensitivity is  
reversed in MEFs from PKR-/- mice, as well as in MEFs transfected with siRNA  
targeting PKR (235). Fourth, the recent crystal structure of ZαADAR1 bound to Z-  
RNA indicate that binding of both Z-DNA and Z-RNA is possible through this  
domain, suggesting that the Zα domain could target dsRNAs containing purine-  
pyrimidine repeats, possibly of viral origin (179). Based on these observations,  
the experimental focus of this chapter was on the N-terminus of E3L, which  
contains a Z-DNA binding domain (121).   
 Preliminary studies have shown that the chimeric virus ZαADAR1- E3LC  
previously described (164) is able to retain its lethality after intracranial  
inoculation (122) suggesting not only that the ability to bind Z-DNA is essential  
to E3L activity but also that both domains need to be linked together in order to  
work. Moreover, studies done in the JC cell line, where N-terminus mutants of  
E3L are unable to replicate, have shown that both wt VACV as well as the  
ZαADAR1- E3LC chimera replicate to similar titers by 72 hours post-infection (data  
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not shown). The present study demonstrates that both the Z-DNA binding domain  
and the dsRNA binding domain of E3L need to be linked together in order to  
inhibit PKR phosphorylation and in order to replicate in JC cells. This was  
assessed by constructing two forms of a dual expression virus, which express  
equally amount of both the Zα domain in the E3L locus and the dsRNA binding  
domain of E3L in the TK locus. These viruses were first tested for their ability to  
rescue a wild-type VACV phenotype in cells in culture as well as activation of  
PKR and subsequent eIF2α phosphorylation. VACVΔE3L, VACVE3LΔ73C and  
VACVE3LΔ73CF were unable to replicate in BSC-40 cells indicating that the  
dsRNA binding domain is necessary for replication in this cell line. Interestingly,  
when comparing the efficiency of plaquing between VACVΔE3LTK::FE3LΔ83N  
and VACVE3LΔ73CF-TK::FE3LΔ83N it was observed that the dual expression  
virus had an EOP value comparable to wt VACV while the EOP of VACVΔE3L-  
TK::FE3LΔ83N was comparable to the control virus VACVE3LΔ83N (Table 2).  
This difference could indicate that the Zα domain could be indeed partially  
rescuing replication in the BSC-40 cell line although further analyses are needed.  
Moreover, VACVE3LΔ73CF-TK::FE3LΔ83Nopp was unable to replicate as  
efficiently as VACVE3LΔ73CF-TK::FE3LΔ83N in this cell line. These results  
correlate with the PKR activation observed at 9 hours post-infection in the HeLa  
cell line where late phosphorylation of PKR was observed for VACVE3LΔ73CF-  
TK::FE3LΔ83N and VACVE3LΔ73CF-TK::FE3LΔ83Nopp with levels of  
phosphorylation higher for VACVE3LΔ73CF-TK::FE3LΔ83Nopp (Fig. 37). The  
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lower replication levels in BSC-40 cells as well as higher phosphorylation levels  
of PKR at 9 hours post-infection in VACVE3LΔ73CF-TK::FE3LΔ83Nopp could  
be due to the fact that transcription in the TK locus with the TK promoter and the  
early optimized promoter going in the opposite direction may be generating more  
dsRNA. These higher levels of dsRNA would not be able to be masked  
effectively by the dsRNA binding domain, activating the IFN-inducible PKR  
protein and affecting replication in the BSC-40 cell line.  
 Neither VACVE3LΔ73CF-TK::FE3LΔ83N nor VACVE3LΔ73CF-  
TK::FE3LΔ83Nopp  were able to replicate in the JC cell line,  similar titers were  
observed in VACVΔE3L, viruses lacking a Zα domain (VACVE3LΔ83N and  
VACVTK::FE3LΔ83N) and viruses lacking a dsRNA binding domain  
(VACVE3LΔ73C and VACVE3LΔ73CF) suggesting that both domains have to  
be linked together for replication in the JC cells (Fig. 39). Based on these and  
previous results a model (Model 1, Fig. 40) that could explain the role of the Zα  
domain of E3L in the activation of the PKR would be that the binding of the  
dsRNA binding domain of E3L to dsRNA causes a torsional strain that generates  
a transient Z-form which would be then bound by the Zα domain of E3L. On the  
other hand, following binding to dsRNA by the dsRNA binding domain of E3L,  
the Zα domain could as well recognize a specific sequence and facilitate and A to  
Z transition (Model 2, Fig. 40). A model indicating PKR activation when using  
the dual expression virus from this study is depicted in Fig. 41. When both E3L  
domains are not linked together, only the dsRNA binding domain would be able  
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to bind to dsRNA, PKR which have been induced by IFN secreted from  
neighboring infected cells would then compete with E3L and bind to dsRNA.  
Binding of two PKR molecules to the same dsRNA will lead to a stable dimer  
which will in turn be phosphorylated rendering PKR active (250).  
 In models 1 and 2, binding of the dsRNA binding domain of E3L to  
dsRNA would increase the affinity of the Zα domain towards dsRNA in its Z-  
form. In order to determine the affinity of the Zα domain of E3L towards Z-RNA,  
some biochemical assays can be performed. One of them would include the  
expression on the Zα domain using a bacterial expression vector. The purified  
expressed protein could then be exposed to chemically synthetic Z-RNA, to be  
obtained through bromination and specific salt concentrations, and their binding  
affinity measure using surface plasmon resonance. Moreover, both Z-forms of  
RNA (ZD and ZL) could be tested in order to evaluate the binding affinities of the  
Zα domain of E3L towards both forms. Because binding of ZαADAR1 to Z-RNA  
has been confirmed using X-ray crystallography (179), binding of the Zα domain  
of E3L to Z-RNA is feasible and would constitute a novel role for this protein.  
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FIG. 30. Double stranded RNA dependent kinase pathway. A virus infected cell  
secretes IFN as a warning signal for nearby cells that are uninfected. IFN induces  
the synthesis of many genes. One of these genes encodes for the protein PKR  
which becomes activated by dsRNA produced as a byproduct of viral infection in  
the host cell. Activated PKR then phosphorylates eIF2α, this inhibits cellular  
mRNA translation, thereby preventing viral protein synthesis. VACV E3L protein  
binds to the dsRNA molecules and prevents binding and activation of PKR  
allowing for viral protein synthesis and replication of the virus.  
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FIG. 31. Schematic representation of the E3L protein. The wild type VACV  
expresses an E3L protein that contains a Z-DNA binding domain (Z-DNA BD) in  
the N-terminus and a dsRNA binding domain (dsRNA BD) in the C-terminus.  
IFNR= interferon resistant.  
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FIG. 32. Domain organization of some proteins with a Zα domain. The following  
proteins are represented: human ADAR1, VACV E3L, mouse ZBP1 and zebrafish  
PKZ. Human PKR is shown as a comparison with PKZ as PKZ has a PKR-like  
kinase activity but has two Zα domains instead of two dsRNA binding domains 
(dsRBD).     
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FIG. 33. Comparison of the amino acid sequence of the Zα domain and dsRNA  
binding domain in VACV E3L and various species with related proteins. (A) Zα  
domains. Residues interacting with Z-DNA based on X-ray crystal structures are  
in bold and highlighted. Homologous residues in proteins whose structure has not  
been determined are highlighted. Sequence of the related human ZβADAR1 is  
also shown as comparison. The recent crystal structure of ZαADAR1 bound to Z-  
RNA indicates that the same residues that participate in Z-DNA binding are  
involved in Z-RNA binding with the exception of R 174 (*). (B) Double stranded  
RNA binding domains. Alignment of VACV E3L double stranded RNA binding  
domain with human proteins known to bind dsRNA. Highlighted residues are  
known to interact with either dsRNA or PKR.  
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TABLE 1. Oligonucleotide primers utilized in plasmid constructions 
  
__________________________________________________________________ 
    Name          Sequence (5'  3')a 
__________________________________________________________________ 
Δ73C-FLAGF         GAATTCGGATCCCCCGGGCTGCCTGAAAAATGTCTAAGATCTATATCG 
Δ73C-FLAGR         GAATTCCTGCAGTCACTTGTCGTCGTCGTCCTTGTAGTCGTTAGCACCTTTCC  
Δ83N-FLAGF         GAATTCGAGCTCAAAAATTGAAAAACTATTCTAATTTATTGCACGGGTTAACG 
Δ83N-FLAGR         GAATTCCCCGGGTCAGAATCTAATGATGACGTAACCAAGAAGTTTATC 
Δ83N-FLAGoppF    GAATTCGAGCTCATAAAAACTGCAGTCAGAATCTAATGATGACGTAACCAAG 
Δ83N-FLAGoppR    GAATTCCCCGGGAAAAATTGAAAAACTATTCTAATTTATTGCACGGG 
J1RF   GAATTCCATATGGATCACAACCAGTATCTCTTAACGATGTTCTTCG 
J1RR   GAATTCGAGCTCGATGACAATAAAGAATTAATTATTGTTCACTTTATTC 
J3RF   GAATTCCCCGGGTATTATATTTTTTATCTAAAAAACTAAAAATAAACATTG 
J3RR  GAATTCCTGCAGTGGATCTCACATCAGAAATTAAAATAATCTTAGAAGGATG   
________________________________________________________________________________________
a Engineered restriction sites are underlined on the primer sequence.  
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FIG. 34. Schematic representation of the constructs engineered to make the 
viruses analyzed in this study. The sequence coding for the Zα domain of E3L is 
driven by the natural E3L promoter (E3LP) in the E3L locus while the sequence 
that codes for the dsRNA binding domain is driven by the early optimized 
promoter (EOP) in the TK locus. The transcriptional stop is denoted by T5NT 
while T5NT* denotes the transcriptional stop for TK. The F denotes the position of 
the FLAG in the construct. 
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FIG. 35. Equal levels of expression of both the Zα domain and the dsRNA  
binding domain of VACVE3LΔ73CF-TK::FE3LΔ83N and VACVE3LΔ73CF-  
TK::FE3LΔ83Nopp. BHK cells were either mock-infected (lane 1) or infected  
with the indicated E3L mutants at an MOI of 5. At 6 hours post-infection, the  
infected monolayers were harvested, separated on a 20% SDS-PAGE gel and  
analyzed by Western blot analysis using antibodies specific for FLAG. Results  
represent three independent assays.  
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FIG. 36. Expression o the Zα domain and the dsRNA binding domain of E3L.  
BHK cells were either mock-infected (lane 1) or infected with the indicated E3L  
mutants at an MOI of 5. At 6 hours post-infection, the infected monolayers were  
harvested, separated on a 20% SDS-PAGE gel and analyzed by Western blot  
analysis using rabbit antiserum against E3L. Results represent three independent  
assays.  
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FIG. 37. PKR phosphorylation assay. HeLa cells were either mock-infected (lane  
1) or infected with the indicated E3L mutants at an MOI of 5. At 4 and 9 hours  
post-infection, the infected monolayers were harvested, separated on a 10% SDS-  
PAGE gel and analyzed by Western blot analysis using specific antibodies against  
the phosphorylated form of PKR (PKR-P). The membranes were then stripped for  
proteins and reprobed with antibodies against PKR. Results represent two  
independent assays.  
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FIG. 38. eIF2α phosphorylation assay. HeLa cells were either mock infected (lane  
1) or infected with the indicated E3L mutants at an MOI of 5. At 4 and 9 hours  
post-infection, the infected monolayers were harvested, separated on a 10% SDS-  
PAGE gel and analyzed by Western blot analysis using specific antibodies against  
the phosphorylated form of eIF2α (eIF2α-P). The membranes were then stripped  
for proteins and reprobed with antibodies against total eIF2α. Results represent  
two independent assays.  
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TABLE 2. Determination of host range in BSC-40 cells. The efficiency of 
plaquing (EOP) is calculated by dividing the pfu/ml in BSC-40 cells by the pfu/ml 
in RK13 cells. 
  
__________________________________________________________________ 
    Virus                                             RK13 cells (pfu/ml)    BSC40 cells (pfu/ml)   EOP 
__________________________________________________________________ 
WT VACV                                   9.5x109 +/- 5.5x108        1.39x1010 +/- 9.03x108      1.47 
VACVΔE3L                                      4.4x109 +/- 6.0x108                 <10                   <0.001 
VACVE3LΔ73C                              2.6x108 +/- 4.0x107                 <10                         <0.001 
VACVE3LΔ73CF                            1.6x108 +/- 6.0x107                 <10                        <0.001 
VACVE3LΔ83N                                     1.1x1010 +/- 3.4x109        1.02x1010 +/- 3.5x109    0.96 
VACVΔE3L-TK::FE3LΔ83N                  1.55x109 +/- 7.5x107       1.27x109 +/- 1.85108     0.82 
VACVE3LΔ73CF-TK::FE3LΔ83N          3.1x109 +/- 1.0x108         4.94x109 +/- 4.38x108    1.59 
VACVE3LΔ73CF-TK::FE3LΔ83Nopp    1.49x109 +/- 3.5x107       5.35x108 +/- 4.23x107      0.36 
_______________________________________________________________________________ 
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FIG. 39. Replication of the dual expression viruses in JC cells. Two sets of  
confluent 35 mm dishes with confluent JC cells were infected at an MOI of 0.05  
with the indicated viruses. Following one hour of incubation the inoculum was  
removed and the cells rinsed with PBS and overlay with the corresponding media.  
At 0 hours and 72 hours post-infection the dishes was harvested and the titer was  
determined in RK13 cells. Error bars indicate the standard error of the mean.  
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FIG. 40. Possible role of the E3L Zα binding domain in the activation of the PKR  
system. In model 1, binding of the dsRNA binding domain causes a torsional 
strain that generates a transient Z-form, which is stabilized by the Zα binding 
domain. In model 2, the Z-DNA binding domain recognizes a specific sequence 
and facilitates the A to Z transition. Z-DNA binding domain=Z DBD, dsRNA 
binding domain=dsRBD.  
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FIG. 41. Model indicating PKR activation in the presence of independent  
expressed proteins made by a dual expression virus from this study. Steps I to III:  
Binding of the dsRNA binding domain to dsRNA, in its A-form, causes a  
torsional strain that generates a transient Z-form (blue). Step IV: In the absence of  
the Z-DNA binding domain in the proximity, the Z-form returns to its original  
configuration. Step V: PKR, which was induced by IFN, will be able to  
successfully compete with the dsRNA binding domain of E3L and bind to dsRNA  
using both of its dsRBD. Binding of two PKR molecules to the same molecule of  
dsRNA leads to formation of stable PKR dimers and dissociation of the inhibitory  
interaction between PKR dsRBD II and its kinase domain. Z DBD= Z-DNA  
binding domain, dsRBD=dsRNA binding domain, KN and KC=N-terminal and C-  
terminal domain of PKR kinase domain respectively.   
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CHAPTER 4 
USE OF MATHEMATICAL MODELS AS TOOLS FOR DENGUE 
RESEARCH 
 
ABSTRACT 
 Dengue is one of the most severe and under-diagnosed vector-borne  
diseases in the world threatening two-fifths of the world population. That is, there  
are 2.5 billion individuals at risk including individuals living in some regions of  
the U.S. World statistics put a range of  50 to 100 million documented infections  
every year including approximately 500,000 severe cases and 22,000 deaths,  
involving mostly children (236). Dengue is a primarily epidemic disease where  
prior strain-specific infections may lead to increased susceptibility to the severe  
potential fatal Dengue Hemorrhagic Fever (DHF) and Dengue Shock Syndrome  
(DSS). There is not yet a vaccine for dengue due to unresolved challenges in the  
development of candidate vaccines (223). While other challenges such as  
education and vector control are also important, attention should be also directed  
towards the understanding of other parameters such as the vector and host  
interactions, vaccine candidates’ effectiveness, dynamics of circulating dengue  
serotypes, vectors life history dynamics, geographical and demographical factors  
as well as the pathogens' evolution. Identifying, implementing and evaluating  
"optimal" solutions that diminish or prevent the spread of dengue, given our  
knowledge and resources, are being explored systematically through the use of  
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mathematical models (38-40, 208) and Murillo, D., Holechek, S., Sanchez, F. &  
Castillo-Chavez, C., manuscript in preparation. This chapter highlights my  
personal perspective as a non-mathematical scientist on the importance of the  
interactions between lab/field scientists and mathematical modelers and  
collaborative efforts that may allow for the best use of "lab" results in addressing  
public health policies over multiple spatial and temporal scales. Modeling  
involves the establishment of quantitative theories and the simulation of  
"realistic" scenarios and in the process one must identify key transmission  
biological parameters (20). A personal review of the mathematical theory and its  
connections to its use in the study of transmission dynamics and control of dengue  
will be reviewed. Data pertinent to the Luciano Castillo Colonna (LCC) region in  
Peru, the region where dengue virus 2 (DENV-2) Asian genotype, dengue virus 3  
(DENV-3) and dengue virus 4 (DENV-4) first entered the country during the  
2000-2001 outbreak will be used as a platform and a preliminary analysis of the  
basic reproductive number will be presented.  
  
INTRODUCTION 
 Infectious diseases have played an important role in the evolution of  
civilizations around the world and are still a prevalent problem for humans  
specially with the continuous travelling within cities (41, 50, 178). Understanding  
the spatio-temporal dynamics of diseases such as dengue, one of the most  
important emerging and re-emerging infectious diseases in the last few decades  
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(93, 98, 178, 236) over multiple scales, requires multidisciplinary and  
transdisciplinary efforts.   
 My personal experience with dengue started while I was working in the  
Molecular Biology Division at the National Institute of Health in Peru. As a  
molecular biologist in charged of the molecular diagnosis of dengue and member  
of the dengue multi-disciplinary team I had the opportunity to witness first hand  
what this disease can do to a country when there is not a prevention plan in place.  
 Walking through the hospitals in Sullana (Piura, LCC region, Peru) filled  
with patients being treated intravenously and children being tested for  
hemorrhagic symptoms was a life changing experience. While many lessons were  
learned as a country during that first dengue outbreak in Peru with hemorrhagic  
cases (154), more questions were raised. Dengue is now endemic in the LCC  
region and in many other areas in Peru, and is an impacting health challenge  
especially with the introduction of new strains into susceptible populations that  
need to be understood and quantified. Here at Arizona State University I had the  
opportunity to interact and collaborate with mathematical modelers with vast  
experience modeling dengue and have come to the conclusion that both fields can  
benefit from each other when trying to understand the larger scale implications of  
dengue as a disease. This is the rationale for adding a chapter to my dissertation  
on the challenges and opportunities posed by the study of complex adaptive  
systems given by the human-vector-dengue dynamics, using mathematical  
models.  
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 I will first review the epidemiology of dengue in order to identify the  
nature of the assumptions that are commonly made by mathematical modelers.  
Different classes of dengue models will be also reviewed and classified in the  
Materials and Methods section according to specific perspectives.  
 The etiological agent of the disease, dengue virus, is a single-stranded,  
positive-sense RNA virus that belongs to the genus Flavivirus, family  
Flaviviridae (49). Dengue has four antigenically different serotypes (DENV-1,  
DENV-2, DENV-3 and DENV-4), each one with the potential of causing disease.  
The pathogenicity of the disease can range from asymptomatic to mild dengue  
fever (DF) to dengue hemorrhagic fever (DHF) and dengue shock syndrome  
(DSS), which affect primarily children (49, 93). According to the World Health  
Organization, 40% of the global population is in risk for dengue infection with an  
estimate of 50 to 100 million infections yearly including 500,000 cases of DHF  
and 22,000 deaths, mostly among children (236).    
 Although dengue has historically been a tropical disease, it now has a  
foothold in the U.S. Dozens of cases have been reported in Florida and it is  
believed that over 5% of the Key West population has been exposed (32). Hence,  
dengue represents a real threat to the U.S., especially considering the amount of  
international travel and high DF prevalence in many regions (156) including  
Southeast Asia, with a 70% increase in cases during the last decade (128).     
 Infection with one dengue serotype does not usually protect against the  
others, and while a secondary infection with a heterologous serotype increases the  
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probability of DHF and DSS (25, 94), there are also reports that indicate that a  
primary infection may be also responsible of severe dengue cases (85, 202, 249).  
The antibody-dependent enhancement (ADE) mechanism also known as the  
immune enhancement theory, explains in part the phenomena observed with  
heterologous infection and it has been observed in vitro for dengue and other  
viruses (95) as well as in the observation of pre-existing immunity to other  
serotypes (155, 226).   
 Another concern about dengue is that differences in severity have been  
associated with particular serotypes and genotypes posing the question that some  
specific genotypes from a determined serotype are more pathogenic than others  
(130). Out of the four dengue serotypes, DENV-2 has been the most frequently  
associated with dengue outbreaks as well as with DHF and DSS (154, 196, 216,  
249), followed by DENV-1 and DENV-3 viruses (11, 98, 154). DENV-4 has been  
associated to milder cases of dengue although it is also capable of causing severe  
infections (170).    
 Heterogeneity in severity is also prevalent within each serotype. For  
example, not all genotypes of DENV-2 are equally virulent. DENV-2 American  
has been the most predominant strain in the Americas prior the early 1980s and  
has not been associated with DHF cases (124, 154). On the other hand, studies  
show the association between DENV-2 Asian and DHF or DSS in young children.  
Thus, the identification of specific DENV-2 genotypes is one of the priorities in  
the study of the epidemiology of the disease (139, 154, 195, 196, 216, 249).  
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 Unfortunately, there is evidence that the more virulent DENV-2 Asian has  
replaced DENV-2 American in certain countries and factors associated with the  
life history of DENV-2 Asian infected vectors seem to be central to this observed  
outcome (154, 195, 216, 249).   
 Dengue is transmitted primarily by the mosquito vector Aedes aegypti,  
which has spread to a vast majority of countries in the tropics and sub-tropics (98,  
193). The secondary vector, Aedes albopictus, has a range that reaches farther  
north than Ae. aegypti and there are reports that its eggs adapt better to  
subfreezing temperatures which increases the risk of a dengue outbreak in the  
U.S. (101, 156). This risk could also be increased due to vertical transmission  
from infected females to eggs. Although previous studies suggested that vertical  
transmission of dengue was not possible (199), recent findings have demonstrated  
that vertical transmission involving Ae. aegypti and Ae. albopictus species is  
feasible in captivity and in the wild  (9, 17, 33, 89, 126, 203). While data indicate  
that the percentage of transovarial transmission observed in Ae. aegypti is low  
(105, 198), certain strain of mosquitoes from determined geographic areas appear  
to be more susceptible to dengue infection and transmission of specific dengue  
serotypes (9, 123, 225). Moreover, data collected from pooled and individual  
mosquitoes from regions where dengue is endemic in Peru strongly suggest that  
Ae. aegypti could be carrying two dengue serotypes simultaneously (26). These  
results corroborate Lorono-Pino’s studies in Asia and Mexico where viremic  
samples from patients were shown to contain more than one serotype (141)  
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matching data obtained from a dengue outbreak in Northwestern Peru in 2008  
(145).   
 There are up to date many dengue vaccine candidates including live,  
attenuated, and vaccines created using recombinant DNA technology such as  
those developed at the U.S. National Institutes of Allergy and Infectious Diseases,  
InViragen, Walter Reed Army Institute of Research/GlaxoSmithKline and Sanofi  
Pasteur, as well as subunit vaccines like those developed by Merck/Hawaii  
Biotech (90). Of these vaccines, the tetravalent dengue vaccine from Sanofi  
Pasteur is currently in Phase III trials in Thailand and results are expected by the  
end of 2012 (91). This vaccine was constructed using the yellow fever vaccine  
17D as a backbone with substitution of the prM and E genes from each dengue  
serotype. This chimeric yellow fever dengue tetravalent dengue vaccine (CYD  
TDV) is a combination of four CYD viruses, one for each dengue serotype, into  
one single vaccine (88, 91).   
 Unfortunately, although there are many dengue epidemiological studies  
that use mathematical and statistical approaches, they are not as widely discussed  
with dengue or field specialists as one would like to see (171). Mathematical  
models with well-determined biological parameters can assess the risk for the  
spreading of dengue and suggest appropriate vector control measures. The  
following section provides a non-expert account of some of the most widely used  
mathematical dengue models into different categories and collects some relevant  
dengue literature that could serve as a starting point for the identification of  
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biological parameters that are key to the development of mathematical dynamical  
models.  
  
MATERIAL AND METHODS 
 Mathematical and epidemiological models. While there are several  
theoretical models for the study of dengue epidemiology (171) their approach as  
well as the biological assumptions that are made are different depending on the  
specific problems that are addressed. Although dengue models differ from each  
other, most share a population dynamics starting point in (51) which has its  
origins in the seminal work of Sir Ronal Ross a British doctor who studied the  
dynamics of malaria at a population level (204) following his extraordinary  
discovery of Plasmodium sp. in the Anopheles mosquito for which he received the  
Nobel Prize in Physiology or Medicine in 1902 (172). Ross' theoretical work in  
mathematical epidemiology was followed by Kermack and McKendrick (116,  
117) and later formalized by MacDonald (143).  
 Mathematical models consider the members of a population (humans or  
mosquitoes) to belong to a specific compartment or classes according to the health  
status of the individuals (20, 55, 104, 232). Moreover, a very interesting  
phenomena called the threshold effect or tipping point rules the dynamics of the  
transition in disease epidemiology and it is associated to biological variables such  
as biting rate of the mosquito (28).  
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 Determining the basic reproductive number (R0). The basic  
reproductive number or R0 is one of the most important concepts when it comes to  
determine the transmission potential of a disease. An R0 equal to 2 indicates for  
example, that a typical single infectious individual will infect on the average two  
individuals if released in a completely susceptible population (104, 232). Thus, R0  
quantifies the strength of an outbreak and is one of, if not the most, important  
number or ratio that needs to be estimated when modeling a disease. There are  
many factors that make difficult to quantify the R0 , i.e. What constitutes a typical  
individual in a heterogeneous population? In many instances, it turns out that  
these models support two types of equilibrium (long-term dynamical outcomes),  
one where there is no disease (R0<1) and one where the disease is endemic  
(R0>1), with R0=1 the threshold or tipping point (28). The value of the effective  
reproductive number or R0e will change over time. Its value will depend on the  
immunity of the population, the heterogeneity of susceptible individuals.  
Generally, if control measures are put in place, for example through the use of  
vaccination campaigns, R0e will decrease. If R0e<1 then the transmission of the  
disease will not be sustained and the outbreak will promptly cease, on the other  
hand if R0e>1, the disease will remain endemic (104).  
 Choosing a model structure. There are three main questions that need to  
be addressed when choosing an appropriate model (232): (1) the natural history of  
the infection, (2) the time period that is going to be modeled and (3) the research  
question that needs to be answered. One of the simplest models is the Susceptible- 
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Infectious (SI) model which can be used to describe for example an HIV infection  
as once a person is infected by another person, he/she will remain infectious for  
life (114). The Susceptible-Infectious-Susceptible (SIS) model is commonly used  
to describe diseases that can be cured but do not provide immunity (81) while  
both the Susceptible-Infectious-Recovered (SIR) and the Susceptible-Exposed  
(Pre-infectious)-Infectious-Recovered (SEIR) models are used for diseases with  
immunizing infections (232) (Fig. 42). Current dengue models usually fall into 
the latest two categories when describing just the infection in the human 
population while a more simple SI coupled model is commonly used when 
classifying the mosquito population (171). More complex models divide the 
mosquito population into four classes: Aquatic, Susceptible, Exposed and 
Infectious, being the last three classes composed of the female adult mosquito 
(247). Moreover, the possibility of vertical transmission in dengue has led to the 
formulation of other models were vertical transmission could be the key for the 
success of a specific strain over another one (Murillo, D., Holechek, S., Sanchez, 
F. & Castillo-Chavez, C., manuscript in preparation).  
 (i) Stochastic vs. deterministic models. Models can also be divided into  
stochastic or deterministic. A deterministic model captures what happens on  
average in a population with a fixed set of parameters while an stochastic model  
allows for a random variation in the number of individuals who go from one  
compartment to another (232). Current dengue models fall into both of these  
categories (62, 171, 178).  
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 (ii) Models with emphasis in the vector. While earlier approaches  
highlight the importance of the use of stochastic models in the study of large-scale  
epidemics (13) the deterministic Container-Inhabiting Mosquito Simulation  
Model (CIMSiM) is one of the most widely known for vector control strategies  
(239). CIMSiM is a dynamic life table simulation model that accounts for  
multiple parameters such as temperature, artificial vs. natural containers,  
development rates of each mosquito stage, gonotrophic cycle, and larval weight  
gain and food depletion. This model uses historical weather data, larval habitat  
and population density in order to produce a simulation that can be tailored to a  
specific region (72, 73, 239).   
  (iii) Models with emphasis in the virus.  
  (a) Sequential models. One of the first models that studied the possible  
acquisition of DHF is the sequential model of which two different scenarios are  
accounted for. The first one assumes that DHF is caused by infection with a  
different dengue serotype (double sequential model), while the second scenario  
assumes infection with two serotypes in the same year and a third different  
serotype in a the following year (triple sequential model) (68).  
  (b) Dengue simulation model (DENSiM). This transmission model builds  
on CIMSiM and accounts for virus development in an infected individual and the  
passage of the virus between human and mosquito populations. It also takes into  
consideration the geographic area, age-specific birth and death rates. The  
temperature and the titer of the virus in the host help determine the extrinsic  
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incubation period in the vector. The virus titer is also use as a measurement of the  
probability for virus transfer between host and vector (71).   
  (iv) Models with emphasis in two dengue strains. There are several  
models that account for the circulation of two dengue serotypes.  
  (a) Competitive exclusion model. The competitive exclusion model by  
Feng & Velasco-Hernandez takes into consideration the co-circulation of two  
strains with temporary cross-immunity, assuming that both strains have a different  
disease progression pattern. This temporary coexistence of these two strains in the  
host population is later disturbed with a resulting competitive exclusion of one  
strain (64) .   
  (b) Coexistence model. This deterministic compartmental model was  
described by Esteva and Vargas where the coexistence of two dengue serotypes  
was feasible for a large range of parameters in contrast to the competitive  
exclusion model described above (60).  
  (c) Antibody-dependent enhancement (ADE) models. There are several  
models that account for the ADE phenomenon. The model by Ferguson et al.  
explores dengue transmission dynamics with the co-circulation of multiple  
dengue strains. As a result, a complex and persistent cyclical or chaotic epidemic  
behavior is generated (67). On the other hand, Kawaguchi's et al. model explores  
genetic and immunological distances among serotypes and how they contribute to  
stable viral communities that allow for a stable coexistence in the population  
(115). While the models above are deterministic in nature, a hybrid stochastic  
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approach has been also formulated where a short period of cross-immunity could  
explain the periodical phenomena of DHF (234).  
 (v) Models with emphasis in control measures. Back in 1975, Dietz  
presented a deterministic compartmental model with vaccination strategies (51).  
In 2003, Derouich et al., proposed a model where both environmental and  
vaccination strategies are discussed in an scenario where one epidemic with a  
virus follows another one with a different one (48). The same year a continuous-  
time Markov chain model for uncertainty analysis was proposed by Luz et al.  
which incorporates vector density spatial heterogeneity, using this model they  
conclude that spatial heterogeneity of the mosquito population makes the risk of  
an epidemic higher and the control measures more complicated (142).  
  Case study: Luciano Castillo Colonna (LCC) dengue outbreaks 2000-  
2010. Data for all the dengue epidemics in the Luciano Castillo Colonna region,  
Piura, Peru were kindly provided by Edwar Pozo, Director of Epidemiology (LCC  
region-Ministry of Health). This data represent the weekly reports of clinically  
confirmed dengue cases by the medical staff based on the World Health  
Organization criteria as well as serological confirmed cases (154, 162).   
 The epidemiological curves for the distribution of dengue cases from  
2000-2010 was done by plotting the number of the epidemiological week in the x  
axis and the number of cases in that week in the y axis and represent a good  
visualization of the dengue status in this endemic region.  
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 Geographic distribution of cases in the LCC region. The total number  
of cases in each province from LCC was converted to a logarithmic scale and  
colors were assigned accordingly in order to provide an easy visualization of the  
number of cases. Similarly, the attack rate (Number of positive cases/Total  
number of the population) per 10,000 individuals was converted to a color scale  
for easier visualization.   
 Age distribution. The age distribution and the attack rate of the confirmed  
cases from 2000-2010 were also analyzed. Of interest is the 0-15 years old  
population as this has been declared by the World Health Organization as the one  
being more at-risk for DHF and DSS (236).  
  Early determination of the reproductive number (R0). The R0 was  
determined by using the following equation previously described by Favier et al.  
(62):  
   (1) 
 
 The force of infection, Λ, is computed by plotting the weekly number of  
cases against the cumulative number of cases. The phase of exponential growth in  
the number of cases can be visualized by a linear growth of the curve. The slope  
of this phase is Λ and its calculated by a least-square linear fit. The parameter  
corresponding to the mortality rate of the (λ), is obtained using the following  
equation:   
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  (2) 
 
where T is the average temperature in Celsius degrees for the epidemiological  
weeks that form the linear phase and Pvd is the vapor pressure deficit in mbar,  
which can be determined using T and relative humidity (RH) data:  
 (3) 
 
The parameters λ1 and λ2 are:  
 (4) 
 
and 
 (5) 
 
 
RESULTS 
 Analysis of the dengue outbreaks from 2000-2010. The weekly number  
of cases was plotted against the epidemiological weeks for the years 2000-2010.  
As it can be observed in Fig. 43, the 2000-2001 dengue outbreak constitutes the  
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outbreak with more number of cases in the LCC region in Piura, Peru. It is know  
that during this outbreak DENV-2 Asian genotype invaded the LCC region and  
replaced the endemic DENV-2 American genotype as evidenced by the genomic  
analysis of the virus extracted from the serum of patients (154). Moreover, it was  
the first time that DENV-3 and DENV-4 also entered the Peruvian territory (154).   
  Other significant outbreaks can be observed in 2003, 2008 and 2010 (Fig.  
43). The number of dengue cases by district was converted to a logarithmic scale  
and colors assigned accordingly (Fig. 44). As it can be observed from 2000 to  
2010, only the districts located in the East side of the region have not registered  
any positive cases for dengue, this is presumably due to colder temperatures and  
higher altitudes which do not favor Aedes aegypti development. Because case  
numbers do not reflect the severity of an outbreak, the attack rates by district were  
also calculated and converted into a color scale (Fig. 45).  
 The age distribution is another important parameter to consider when  
analyzing outbreaks specially because the more severe forms of dengue disease,  
DHF and DSS, have been associated with children under 15 (12, 84, 86, 93). As it  
can be observed in figure 46 the 15-29 age group was the most affected 
throughout 2000-2010. When analyzing the attack rate per age groups,  
proportional attack rates were observed among the groups (Fig. 47).  
 Estimation of the R0 and the force infection (Λ) for the 2000-2001  
dengue outbreak. The 2000-2001 outbreak in LCC was chosen as this represents  
the first reported dengue outbreak in Peru with confirmed DHF cases as well as  
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the introduction of the DENV-2 Asian genotype and the DENV-3 and DENV-4  
(154). There are many methods to estimate the R0 for vector-borne diseases using  
real epidemics data (147). The method used in this chapter is a preliminary  
attempt to estimate the R0 based on the initial cumulative number of cases and has  
previously been adapted to vector-borne diseases (62, 178). This method is based  
on the assumption that at the beginning of an outbreak the hypothesis of  
homogeneous mixing can be satisfied (63). When plotting the number of new  
cases per week against the cumulative number of cases, the phase of exponential  
growth of the cumulative number of cases can be evidenced by a linear growth of  
the curve. The slope of this line is the force of infection (Λ) and is obtained by  
computing a least-square linear fit of this linear phase (62, 178). When analyzing  
the initial exponential growth of the 2000-2001-dengue outbreak the Λ was found  
to be 0.462 (Fig. 48). Based on Λ, R0 was estimated by only using two parameters  
for the host (1) γ = inverse duration of the host viremia and (2) τi = intrinsic  
incubation period and two parameters for the vector (1) λ = mortality rate of  
vectors and (2) τe = extrinsic incubation period (62). The host parameters have  
been previously described (149). The parameters for the mosquito population are  
dependent on the temperature and have been modeled by Favier et al. (62) based  
on previous models (71, 72). By using the formulas 2, 3, 4 and 5 described in the  
materials and methods section, the parameters needed to solve equation 1 were  
found and are described in Table 3. The R0 for the 2000-2001 dengue outbreak in  
the LCC region calculated using equation 1 was 6.24.  
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DISCUSSION 
 The use of mathematical models have proved to be useful in the analysis  
of vector-borne diseases such as dengue and has evolved over time to encompass  
complex models that take into consideration the interaction between the human  
and vector populations on complex environmental landscapes (171). While there  
is not a gold standard for a dengue model, the current approaches are tailored to  
specific needs with respect to the virus (60, 64, 67, 115, 234), the vector (72, 73,  
239) and the dynamics of an epidemic (48, 51, 142). From a biological  
perspective mathematical models could help us understand dengue at a bigger  
scale. One of the questions that modeling can help answer is for example what  
would be the effect of the invasion of a specific dengue strain into an area where  
an endemic strain is already circulating. In this scenario two broad categories of  
invasion could be observed. First, an area will be endemic with a strain other than  
DENV-2. Then, either DENV-2 Asian or American may attempt to invade.  
Secondly, a susceptible mosquito will become infected with either DENV-2 Asian  
or American genotype and vertical transmission of one of the DENV-2 genotypes  
in the vector could be considered. This model could explain the displacement of  
DENV-2 American genotype by the Asian genotype as well as the speed and  
severity of dengue outbreaks in countries like Peru where the DENV-2 Asian  
genotype was first introduced during the 2000-2001 epidemic (154). Prior to the  
appearance of DENV-2 Asian genotype in northwestern Peru, only DENV-1 and  
DENV-2 American genotype were circulating (124, 154). The absence of DHF  
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and DSS in the northeastern Peruvian city of Iquitos prior 2000 could be due to  
the cross-immunity conferred by DENV-1 against DENV-2 American genotype  
but not to the DENV-2 Asian genotype suggesting that the American genotype  
may have a DENV-1 like antigen (124). Moreover, there are data that indicates  
the presence of genetic variability between A. aegypti mosquitoes from the coast  
and the ones from the Peruvian northeast area (138), indicating that there could be  
a specific genetic variant responsible for the dissemination of DENV during the  
2000-2001 dengue outbreak in Peru.   
 A model that includes vertical transmission, and its association with a  
more virulent strain like DENV-2 Asian genotype, should be taken into  
consideration for the prediction of dengue outbreak outcomes. Of all the 2000-  
2010 dengue outbreaks in the LCC region, the 2000-2001 outbreak is of  
significant importance as it marks the invasion of DENV-2 Asian genotype,  
DENV-3 and DENV-4 to the Peruvian territory (154). When determining the  
early reproductive number of this outbreak it was found to be 6.24, an estimate  
that is comparable to what has previously been found by modelers when  
analyzing real epidemiological data including previous work done in Peru  
involving the study of the spatial and temporal dynamics of dengue fever between  
1994 and 2006 (R0= 0.1 to 112.8) (40). Other estimates of the R0 using the same  
method described in this chapter with real epidemics data from different Brazilian  
regions during 1996 to 2003 gave R0 values from 2.1 to 103 (62). Further analyses  
of other outbreaks using this method and other methods are necessary in order to  
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validate if the early determination of the R0 using the initial exponential growth of  
an outbreak is indeed more valuable than other approaches.  
 In the absence of an effective vaccine, worldwide efforts should be made  
to monitor Aedes mosquitoes, both males and females, and the DENV serotypes  
and genotypes that are being carried and transmitted. A mathematical model of  
this nature would be used to not only highlight the importance of vertical  
transmission in a dengue outbreak but also the importance of epidemiological  
surveillance incorporating molecular genotyping. Routine detection of the virus in  
both mosquitoes and hosts in endemic areas with dengue will be valuable in  
efforts to prevent major outbreaks. Interdisciplinary efforts should be encouraged  
in order to validate theoretical models with real life data.  
 Another aspect where models can be helpful is in the evaluation of  
implementation policies. Despite massive campaigns to eradicate dengue, results  
so far have been short-lived and many countries support control programs that are  
not very successful. Among the factors to be blamed are the limited government  
resources, increased growth of urban areas, inadequate trained personnel, reliance  
on insecticides, resistance to insecticides, reliance on government intervention  
and lack of education with respect to dengue (193). Moreover, failure of dengue  
control campaigns has also been attributed to the misconception that reduction of  
the Aedes population would stop transmission altogether. Large government-led  
programs are costly and become difficult to maintain, particularly if they have  
been successful for a long time (193). It has been observed that the dengue  
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surveillance program in Puerto Rico, one of the best in the world, is ineffective  
because of the lack of community involvement (83). Creating sustainable dengue  
control strategies require an innovative approach, one that moves away from the  
centralized top-down model into a decentralized bottom-up community-based  
model. A great example of a powerful community-based program is Project  
HOPE which trained community leaders in early disease detection and increased  
awareness in the population (183).    
 Many countries have implemented several prevention and awareness  
programs after they were affected by a dengue outbreak. In 2000, for example,  
although familiar with dengue, local Peruvian health officials were unprepared for  
the threat of DHF, and many severe cases developed before hospitals were able to  
successfully diagnose the disease. Evidence indicates that the outbreak was  
caused mainly by the introduction of a virulent strain from Asia where many DHF  
cases are reported (154). Following this outbreak, several educational resources  
have been put in place including marches, dengue-related games, yearly calendars  
showing months were dengue is expected, street performers and dissemination of  
dengue information through theater, radio campaigns and press (182). Currently  
all four dengue serotypes are endemic to Peru, including the LCC region where it  
has rapidly expanded (182). It is still too early to evaluate how effective these  
measures have been in the affected population. Other countries such as Singapore  
have adopted new strategies to get rid of dengue involving children in  
environmental campaigns and using the cyberspace to launch platform games  
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such as M.A.C.E. (Monster Annihilation and Control Enforcement) that are  
designed to create awareness of dengue prevention among the young population  
(215).  Moreover, Ministry of Health leaders from some small communities in  
Costa Rica have observed that despite knowledge of the disease and its  
transmission, failure will be in the horizon if there is not a sense of community  
where leaders work together to reinforce the Ministry of Health suggestions and  
regulations regarding dengue (1).   
 All these reasons provide great opportunities for the evaluation of dengue  
prevention strategies, which can be evaluated using models that reflect the need  
and resources of each country as well as the biological fingerprint of the disease  
endemic to each region. Moreover, the relatively fast and inexpensive nature of  
working in silico provides a great tool for building models that examine problems  
at large scales. The need exists for expanding the interaction between biologists  
and mathematical modelers and bring the best of their expertise to better  
understand and ameliorate diseases like dengue which threatens two fifths of our  
world population (236).  
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FIG. 42. Common model structures used to describe the transmission of diseases.  
S=Susceptible, E=Exposed/Pre-infectious, I=Infectious, R=Recovered/Immune.  
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FIG. 43. Weekly numbers of dengue fever cases during 2000-2010 in the Luciano  
Castillo Colonna region, Piura, Peru.  
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FIG. 44. Number of dengue cases by district in the Luciano Castillo Colonna 
region, Piura, Peru (2000-2010). A colored logarithmic scale was created in order 
to highlight areas with more concentration of cases. 
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FIG. 45. Dengue attack rates by district in the Luciano Castillo Colonna region,  
Piura, Peru (2000-2010). Colors indicate the number of positive cases per 10,000  
individuals.  
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FIG. 46. Age distribution of dengue cases in the Luciano Castillo Colonna region,  
Piura, Peru (2000-2001).  
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FIG. 47. Dengue attack rates by age groups in the Luciano Castillo Colonna  
region, Piura, Peru (2000-2010).   
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FIG. 48. Weekly number of cases against the cumulative number of cases for the  
2000-2001 dengue outbreak in the Luciano Castillo Colonna region, Piura, Peru.  
The dashed box indicates the growing linear part of the plot corresponding to the  
initial exponential growth of the outbreak. The least-square linear fit of the linear  
phase gives Λ=0.462±0.02 with correlation coefficient R≈1.0.  
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TABLE 3. Parameters used to estimate the basic reproduction number (R0) for the  
2000-2001 dengue outbreak in the Luciano Castillo Colonna region, Piura, Peru.  
 
_______________________________________________________________________________ 
Parameter Description      Value 
__________________________________________________________________ 
Λ (day-1)a  Force of infection      0.066  
T (°C)b Average temperature      23.70 
RH (%)b      Percentage of relative humidity    56.42  
Pvd b    Vapor pressure deficit     12.8   
γc  Inverse of the duration of host viraemia  0.167 
λ (day-1)c Mortality rate of the vectors    0.2 
τe (day)b Extrinsic (vector) incubation period   13.2 
τi (day)c Intrinsic (host) incubation period   5 
__________________________________________________________________ 
a Force of infection found using the slope in Fig. 48 was divided by 7 in order to  
obtain the daily value.  
b Parameters calculated by using epidemiological and climatological data from  
weeks 18 to 24 (2000).  
c Parameters established by Favier et al. (62)  
 
  
  
  
  
  
 
 
 
 
 
 
 
 
 
  
 150 
OVERALL DISCUSSION 
 Since the pioneering work by Edwar Jenner and the establishment of the  
field of vaccinology back in 1796 (46), numerous efforts have been made in the  
lab and in silico to eradicate several diseases that impact not only the affected  
individuals but also the local and global economy. Although thanks to Jenner  
smallpox has been declared eradicated by the World Health Organization (4, 237),  
there is still the need to continue studying VACV, a virus that has been used as a  
vaccine for smallpox as it confers immunity to the disease (108). Moreover,  
VACV is also used as a recombinant vector for its potential to provide protection  
against other diseases (77, 108, 120, 158, 176, 248).   
 Unfortunately, inoculation in humans with VACV can cause mild to, in  
some cases, life-threatening reactions (58, 127, 206). After September 11, 2001,  
the concern arose for the use of VARV or monkeypox virus (MPXV) as a  
bioterrorism agent and the risk of an accidental VARV release (134, 169, 227).   
For all these reasons the developing and optimization of a post-exposure  
prophylaxis vaccine against smallpox was necessary. Chapter 1 describes the  
optimization of a recombinant VACV, v50ΔB13RMγ, as a post-exposure  
prophylactic agent in a VACV animal model. This virus is able to protect mice  
following exposure to 100LD50s of wt VACV when is administered 1 dpi with  
100% survival. This protection is dose and time dependent as treatment at 2 or 3  
dpi increases morbidity and diminishes survival. When looking at the mechanism  
of action of this virus it was observed that although the mice survived and  
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 obtained a health status comparable to uninfected mice by day 18 post-infection,  
viral replication was similar in the organs from wt VACV infected animals as  
well as in the ones that were infected with wt VACV and then treated with  
v50ΔB13RMγ. These data suggest that v50ΔB13RMγ is acting as an  
immunoregulator rather than as an antiviral. In Chapter 2 the mechanisms that  
v50ΔB13RMγ could be using to prevent morbidity and mortality were explored.  
Preliminary data indicate that v50ΔB13RMγ has an effect in viral replication in  
the olfactory bulb but not in the rest of the brain. Although poxvirus replication  
has already been observed in the olfactory bulb (21, 146, 189) recent data form  
our lab (Karen Denzler, unpublished data) have shown that the blood brain barrier  
(BBB) permeability is affected following infection with wt VACV. While  
v50ΔB13RMγ seems to be halting replication in the olfactory bulb of treated  
animals, wt VACV could be crossing the BBB which plays an important role in  
post-vaccinal encephalitis (76).   
 IFN-γ induces a variety of immune responses, when examining the  
immune cells that were recruited at the site of infection, CD8+ T cells and the  
heterogeneous Gr1+CD11b+ cells, also known as myeloid derived suppressor cells  
(MDSCs), were observed in more numbers in the mice treated with v50ΔB13RMγ  
which would indicate a potential role of these populations during post-exposure  
although more analyses are needed as subpopulations of  MDSCs have been  
depicted to have several roles under healthy and pathological conditions (148,  
165, 230, 251). Recent studies have identified that a subpopulation of  
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Gr1+Cd11b+ cells not only produce type I IFN but also exhibit tissue protective  
properties following peripheral virus infection by producing reactive oxygen  
species (69). Future studies include the depletion of Ly6G+ cells in order to  
evaluate their role during post-exposure prophylaxis using v50ΔB13RMγ as they  
could be indeed protecting infected tissue from immune-mediated damage.  
The reasons why a better understanding of VACV is important have  
previously been mentioned. One of VACV innate characteristics is that it is IFN-  
resistant. This is primarily due to the E3L gene (106) which is also important for  
pathogenesis in mice (19, 122). E3L produces a 25-kDa protein that has two   
domains; an N-terminal domain that belongs to the vertebrate Zα family of Z-  
DNA binding domains (110, 121, 122, 129), and a C-terminal domain with a  
typical double-stranded RNA (dsRNA) binding domain (34, 43, 133). Recent data  
suggest that not only the dsRNA binding domain but the Z-DNA binding domain  
play a role in evading the host IFN response (235). In Chapter 3 a virus was  
engineered containing both domains of E3L in different loci of the VACV. This  
virus was tested in the murine JC cell line, the only cell line so far available where  
the Z-DNA binding domain is necessary for VACV replication (228). If indeed  
both domains can work independently, replication was expected in this cell line  
comparable to wt VACV levels. When viral titers were analyzed after 72 hours of  
infection with the input virus, no changes were noticed with the exception of wt  
VACV. When looking at the activation of the dsRNA dependent protein kinase  
(PKR) at late times post-infection, PKR phosphorylation was observed in cells  
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infected with the dual-expression virus suggesting that it was unable to bind and  
mask dsRNA synthesized during VACV infection. These results indicate that both  
domains of E3L need to be linked together in order to inhibit the IFN response.  
Future studies will include expression of the Z-DNA binding domaing using a  
bacterial expression vector and evaluating its affinity to Z-RNA using surface  
plasmon resonance. Based on previous data obtained with ADAR1, which also  
has a Z-DNA binding domain and binds both Z-DNA and Z-RNA (179), it is  
possible that the N-terminus of E3L could bind to a transient Z-RNA that could  
result from a torsional strain following binding of dsRNA by the dsRNA binding  
domain.  
 Another strategy that is used in the scientific field to study viruses is  
mathematical modeling. Because smallpox has already been eradicated, the utility  
of mathematical modeling as a tool for predicting the outcomes of disease spread  
was explored in Chapter 4 using dengue as a disease model. Dengue is one of the  
most complex and important emerging and re-emerging infectious diseases in the  
world  (93, 98, 178, 236). The most important challenge for dengue is that there is  
not yet a commercial available vaccine although many efforts are being made by  
diverse research groups (53, 90, 91).  The last chapter looks into some of the  
current dengue models and uses data from the 2000-2001 dengue outbreak in Peru  
as an example of how important the biological parameters are in order to obtain  
preliminary data when a dengue outbreak strikes a susceptible population. While  
the current Phase III clinical trials for vaccine candidates is still in process, the  
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World Health Organization is looking into the use of mathematical modeling to  
predict vaccination strategies (238). This will not be feasible without the expertise  
not only from mathematical modelers but that of clinicians, vaccinologists,  
virologists, immunologists, entomologists and epidemiologists. Thus, the last  
chapter highlights the importance of interdisciplinary collaboration and how it  
benefits research on infectious diseases.  
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